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General introduction and outline of the thesis
1 General introduction and outline of the thesis
During early embryonic life, primordial undifferentiated germ cells proliferate 
through 20-30 mitotic divisions and, subsequently, differentiate into primary 
oocytes when the ovaries are formed. At birth, all of the primary oocytes have 
entered a phase of maturation arrest, known as dictyotene, in which they remain 
until the first meiotic division is completed at the time of ovulation. After this, a 
second meiotic division starts during which fertilisation can occur. The meiotically 
arrested oocytes form individual primordial follicles, the resting pool of oocytes, 
which is fixed during embryonic life. A proportion of these primordial follicles 
undergoes a gonadotropin-independent recruitment to enter the growing pool of 
primary follicles. After pubertal onset a cyclic recruitment of a limited number of 
follicles from the growing antral follicle pool will escape atresia by an increase in 
circulating follicle stimulating hormone (FSH) levels. FSH and luteinizing hormone 
(LH) are the pituitary gonadotropins coordinating antral follicle development and 
ovulation. During reproductive life the continuous recruitment and apoptosis of 
resting follicles leads to a gradual decrease in the primordial follicle pool. 
Exhaustion of the dormant primordial follicle pool at the end of fertile life results in 
amenorrhea and menopause.
1.1 The phenotype of primary ovarian insufficiency
Though most women reach menopause between 45 and 55 years of age, 1% of 
the general population becomes postmenopausal before the age of 40. Women 
who have amenorrhea for at least 4 months with two FSH serum levels in the 
postmenopausal range (>40 lU/l) before the age of 40 are diagnosed with primary 
ovarian insufficiency (POI). POI has previously been referred to as ‘premature 
menopause’ and is often still called ‘premature ovarian failure’ (POF). Because of 
the complicated clinical presentation and course of this condition (see below), 
questions have been raised about the annotation of ‘premature ovarian failure’ for 
this condition. The evidence that follicle development and ovulation are common 
among women diagnosed with POF (1-3) suggests that the term POF is not 
accurate. The word ‘failure’ falsely suggests an indefinite state and does not 
encompass intermittent ovarian function. Therefore, a more accurate term to 
describe the state of ovarian function is primary ovarian insufficiency, POI (4-6). 
POI exhibits a heterogeneous phenotype, i.e., amenorrhea can present either as 
a primary event, with a variable degree of secondary sex characteristics or, more 
commonly, as a secondary event after an episode of menstrual periods and/or 
pregnancies. POI may constitute part of a syndrome or may represent a 
non-syndromal phenotype. The age of onset varies widely from pubertal age up 
to 40 years old. Approximately half the number of patients have oligomenorrhea
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or shortening of the menstrual cycle length before amenorrhea starts, whereas 
25% show a more acute onset of sudden amenorrhea when periods do not restore 
after cessation of oral contraceptive (OC) use, which was masking cycle irregularity 
and amenorrhea, or after pregnancy and delivery (7). POI is distinct from 
menopause since 50% of the women with POI have an unpredictable ovarian 
function (2;8;9) and a 5-10% life-time chance of becoming pregnant (10).
1.2 Etiology of POI
The etiology of POI may be due to genetic or non-genetic causes. The genetic 
causes are represented by either gross chromosomal abnormalities (i.e., 
X-chromosome abnormalities in Turner syndrome or balanced autosomal 
translocations), gene mutations (i.e., the galactose-1-phosphate uridyl transferase 
(GALT) and fragile X mental retardation 1 (FMR1) genes), or polymorphisms (i.e., 
FSH receptor polymorphism). The non-genetic causes are represented by 
autoimmune diseases (i.e., autoimmune lymphocytic oophoritis, autoimmune 
polyglandular syndrome), infectious diseases (e.g. mumps) or iatrogenic factors 
(i.e., bilateral oophorectomy, chemotherapy or radiation procedures). However, 
these causes underlie only a small proportion of POI cases. The majority remains 
unknown and is referred to as idiopathic POI. An overview of most currently known 
gene mutations, including candidate genes, associated with POI are listed in 
Table 1. Even though the genetic causes of POI have been explored widely, the 
currently known chromosomal anomalies and gene mutations only account for a 
small m inority of cases of ovarian insufficiency, which is in conform ity with its 
heterogeneous nature and suggests that there must be additional factors that 
remain to be identified.
1.3 Assessment of genetic factors involved in POI
Recent advances in human genetics, including high-resolution linkage analysis, 
genome-wide association studies, high-throughput genome copy number 
profiling and next-generation sequencing, have facilitated the elucidation of 
causal genetic factors underlying various hereditary and acquired human 
diseases, including congenital syndromes.
Cytogenetic analysis
Chromosomal abnormalities have been identified through karyotyping. For 
women with POI, besides Turner syndrome, various translocations have been 
identified by karyotyping. Through breakpoint mapping of X-autosome 
translocations, Therman et al. (11) were the first to identify two regions critical for 
POI, at that time referred to as premature ovarian failure (POF), called POF1 and 
POF2. POF1 extends from Xq21 to qter and harbours the FMR1 gene. POF2
12
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Table 1 Genetic and non-genetic factors associated with spontaneous 
primary ovarian insufficiency (POI)
Syndromal POI *
Syndrome (OMIM
number)
Gene Cytogenetic
location
Fragile X-associated disorders (309550) FMR1 Xq27.3
Autoimmune polyendocrine syndrome, type 1 (240300) AIRE 21q22.3
Autoimmune polyendocrine syndrome, type 2 (369200) Unknown 15q21.1
Congenital adrenal hyperplasia due to 17-alpha 
hydroxylase deficiency
(202110) CYP17A1 10q24.3
Lipoid congenital adrenal hyperplasia (600617) STAR 8p11.2
Aromatase deficiency (107910) CYP19A1 15q21.1
Blepharophimosis, ptosis, epicanthus inversus 
syndrome
(110100) FOXL2 3q22.3/3q23
Progressive external ophthalmoplegia with 
mitochondrial DNA deletions
(157640) POLG 15q25
Galactosemia (230400) GALT 9p13
Congenital disorder of glycosylation, type 1A (212065) PMM2 16p13.3-p13.2
Fanconi anemia (227650) FANCA, FACA, 
FA1, FA, FAA
16q24.3
Ataxia telangiectasia (208900) ATM 11q22.3
Bloom syndrome (210900) BLM 15q26.1
Werner syndrome (277700) WRN 8p12-p11.2
Rapp-Hodgkin syndrome (129400) TP73L 3q27
Demirhan syndrome (609441) BMPR1B 4q23-24
Marinesco-Sjogren syndrome (248800) SIL1 5q31
Leukoencephalopathy with vanishing white 
matter
(603896) EIF2B2
EIF2B4
EIF2B5
14q24
2p23.3
3q28
Mental retardation, X linked (309548) FRAXE Xq28
Perrault syndrome (233400) Unknown
Malouf syndrome (212112) Unknown
Woodhouse-Sakati syndrome (241080) Unknown
Bassoe syndrome (254000) Unknown
Cerebellar ataxia with hypergonadotropic 
hypogonadism
(605672) Unknown
Fryns syndrome (49599) Unknown
* Adapted from Nelson (12)
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Table 1 Genetic and non-genetic factors associated with spontaneous 
primary ovarian insufficiency (POI)
Non-syndromal POI **
Gene Cytogenetic location
Genetic factors associated with POI
Chromosomal abnormalities
Genes associated with POI BMP15 Xp11.2
NOBOX 7q35
NR5A1 9q33
FIGLA-genes 2p13.3
FSHR gene 2p21-p16
LHR gene 2p21
Candidate genes POF1B Xq21.2
DIAPH2 Xq21.3
DACH2 Xq21.2
GDF9 5q31.1
ADAMST19 5q31
ACSL6 5q31
PTHB1 7p14
ESR1 6q25.1
AR Xq11-q12
BCKDHB 6q14
DMC1 22q13
MSH5 6p21.1-p21.3
INHA 2q33-q36
PCMT1 6q22.3-q24
Candidate genes based on animal models ZFX Xp22.1-p21.3
FOXO3a 6q21
TAF4b 18q11.2
LHX8 1p31.1
Sohlhl 9q34.3
Sohlh2 13q13.3
Rfpl4 19q13.4
Candidate regions POF2 Xq13.3-q22
containing candidate genes POF1 Xq21-qter
not applicable 9q21.3
not applicable Xp21.3
** Modified table from Nelson (12) and Van Dooren (13)
14
General introduction and outline of the thesis
Table 1 Genetic and non-genetic factors associated with spontaneous 
primary ovarian insufficiency (POI)
Non-syndromal POI **
Gene Cytogenetic location
Non-genetic factors associated with POI
Autoimmune disease 
APS I&II 
Hypothyroidism 
Addison’s 
DM type 1
Congenital thymic aplasia 
Infectious
Mumps oophoritis 
Iatrogenic
Chemo/surgery/radiation
Idiopathic
** Modified table from Nelson (12) and Van Dooren (13)
extends from Xq13.3 to Xq22 and harbours the candidate genes DACH2, DIAPH2 
and a candidate gene confusingly called POF1B.
Linkage analysis
When genetic markers became available not only cytogenetic analysis, but also 
linkage analysis could be applied to explore genetic defects involved in POI. 
Because DNA segments that lie near each other on a chromosome tend to be 
inherited together (co-inheritance), markers are often used to track the inheritance 
pattern of a gene that has not yet been identified. Linkage analyses are typically 
performed within families containing several affected individuals. For these 
analyses, various markers have been used, i.e., initially a few hundred evenly 
spaced microsatellite or polymorphic markers were used, whereas currently high- 
throughput microarray platforms are employed containing 250,000 or more single 
nucleotide polymorphisms (SNPs). By doing so, statistically significant co-inheritance 
of genomic regions between affected relatives can be tested, which results in a 
logarithm of odds (LOD) score. The higher the LOD score, preferably above 3, the 
lower the odds that the observed co-inheritance was by chance.
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Among the idiopathic POI cases the familial prevalence varies from 4% to 31% 
(9;14;15). Aittomaki et al. (16) systematically searched for linkage in multiple 
affected families and, by doing so, mapped a locus for POI, at that time called hy­
pergonadotropic ovarian dysgenesis, to chromosome 2p. Subsequently, they 
identified a mutation in the previously cloned FSH receptor gene within that 
region. More recently, two Dutch research groups identified three novel candidate 
loci by genome-wide linkage analysis on the chromosomes 5, 9 and X, respectively 
(17;18).
Worldwide, only a limited number of linkage analyses have been performed, 
because for proper linkage analysis families with multiple affected individuals are 
required. Large families with POI are scarce due to inherent reproduction 
problems.
Association studies
The completion of the Human Genome Project in 2003 and the International 
HapMap Project in 2005 yielded a reference of the human genome sequence and 
of human genetic variations in terms of SNPs. The concom itant development of 
high-throughput genomic microarray platforms (see above) also made it possible 
to quickly analyse whole genome samples for genetic variations that are more or 
less common in affected individuals as compared to the general population. The 
associated genetic variations can serve as powerful pointers to regions of the 
human genome in which the disease-causing factor may reside. However, the 
associated variant (SNP) itself may not directly cause the disease, and thus 
further sequencing of DNA in that particular region of the genome is required to 
indentify the exact genetic change. In contrast to linkage analyses, genome-wide 
association studies (GWAS) deliver more power to detect genetic causes of 
modest effects on the etiology of complex multifactorial diseases such as POI. In 
the past few years GWAS for POI have been conducted and indeed, through this 
strategy, several candidate loci and candidate genes such as PTHB1 (19), 
ADAMTS19 (19;20) and BCKDHB (21) have been identified.
Both linkage analyses and association studies require sequencing of candidate 
genes in order to identify the underlying genetic cause. The recent development 
to sequence not only one or a selection of genes, but whole genomes by next- 
generation sequencing, holds great promise for the identification of genes 
involved in POI.
Copy number profiling
In contrast to the gross resolution of karyotyping, DNA copy number profiling by 
array comparative genomic hybridization (arrayCGH) allows the detection of sub- 
m icroscopic chromosomal imbalances with an almost infinite resolution. Two
16
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differently labeled genomic DNA samples, one of test DNA and one of normal 
control DNA, are compared by simultaneous hybridizations. The intensity of the 
fluorescent signal depicts the copy number ratio. As for GWAS, also for arrayCGH 
analysis selected regions and candidate genes require further examination, for 
example through the establishment of expression patterns of these candidate 
genes in tissues and organs of interest. Aboura et al. (22) were the first to perform 
arrayCGH analysis in a POI population and found eight relevant copy number 
variants (CNVs), both in autosomal regions and on the X chromosome.
Candidate gene approach
Another way to identify genes important in disease development is the candidate 
gene approach (CGA), which directly tests the effects of a potentially contributing 
gene. However, the CGA is limited by knowledge about the etiology of the disease 
and the functional annotation of genes. So far, most candidate genes for POI 
derived from animal models have been assessed by CGA. The selection of 
candidate genes is based on their putative involvement in embryonic oocyte 
development or the process of follicle recruitment. Qin et al. (23) used a CGA 
based on mouse model studies and, through this approach, found SNPs and 
CNVs in the NOBOX gene associated with POI in humans. In another study, Zhao 
et al. (24) confirmed the identification of FIGLA (Factor in the GermLine, Alpha) as 
a candidate gene based on a mouse model through the identification of mutations 
in the FIGLA gene in women with POI.
1.4 Oogenesis and folliculogenesis
During fetal life primordial germ cells give rise to oogonia through mitosis (see 
above). For this mitotic process several genes are suggested to be involved, 
mostly identified via animal models, such as Bone Morphogenetic Protein 4 
(BMP4), RNA binding protein TIAR, and zinc finger protein, X-linked (Zfx) (25). By 
their rapid proliferation the primordial germ cells give rise to a maximum of 6 to 7 
million oogonia at 16-20 weeks of gestation (26). At that point transformation to 
oocytes by entering the first meiotic division has been initiated. These oocytes, 
which are arrested, comprise the primordial follicle pool. Several specific factors 
have been identified to play a role in the formation of primordial follicles, such as 
SPO11, DMC1 (Dosage suppressor of mck1 homolog) and MSH5 (MutS protein 
homolog 5) (27), all of which cause meiotic arrest. A germline specific transcription 
factor, FIGLA, and NOBOX (Newborn ovary homeobox) regulate the expression 
of genes involved in oogenesis. From the m id-gestational peak on, the germ cell 
population starts an inevitable exponential decline via apoptosis (28) and falls 
from 1 to 2 million at birth to between 300,000 and 500,000 at puberty. The B-cell 
leukemia/lymphoma-2 (Bcl-2) family of proteins plays an important role in the
17
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regulation of apoptosis in various tissues, including the reproductive tissues (29), 
and encompasses both anti-apoptotic and pro-apoptotic proteins. Apoptosis 
may also be induced by other factors such as tum or necrosis factor a  (TNFa) and 
gonadotropin-releasing hormone (GnRH) (30).
Over the next 35-40 years of reproductive life, only about 400-500 oocytes will 
ovulate, the rest are lost through atresia. In the ovary, gonadotropins, estrogens, 
growth hormones, growth factors, cytokines and nitric oxide act in concert to 
ensure the survival of pre-ovulatory follicles (28). Recruitment of primary follicles 
into the pool of growing follicles is regulated by members of the TGF p superfamily, 
such as anti-Mullerian hormone (AMH), which inhibits initial recruitment. Mouse 
models also suggest an important role for proteins acting in the PI3-kinase 
pathway in this recruitment. Further follicle maturation depends on hypothalamic- 
pituitary-gonadal interactions, where FSH becomes essential for granulosa cell 
proliferation and the prevention of apoptosis by BMP15, GDF9 and TGFp, which 
promote cell survival (31), and LH receptor expression. AMH, produced by 
granulose cells of preantral and small antral follicles, has an inhibitory effect on 
follicle growth by diminishing the sensitivity of follicles for FSH stimulation. The 
LH surge will induce resumption of meiosis, arrest at meiotic stage II and 
subsequent ovulation of the oocyte, awaiting fertilization to complete meiosis.
By comparing AMH serum levels of FMR1 premutation carriers, who overall have 
an earlier menopause, to that of non-carriers revealed lower AMH levels in the 
premutation carriers. These lower levels imply a lower amount of preantral and 
small antral follicles after initial recruitment from a subsequently smaller resting 
follicle pool or ovarian reserve (32).
1.5 The FMR1 gene
Despite all extensive efforts made to identify oogenesis and folliculogenesis 
pathways, as yet only a small m inority of POI cases can be explained. We focused 
on the most common hereditary causes of POI, i.e., a premutation of the fragile X 
mental retardation (FMR1) gene (33-37). This hereditary cause is mostly referred 
to as fragile X-associated primary ovarian insufficiency (FXPOI). The premutation 
represents an expansion of a trinucleotide (CGG) repeat in the 5 ’ untranslated 
region of the FMR1 gene (38) up to 55-200 CGG repeats. This CGG repeat, with 
a median length of 30 copies, occurs in every individual’s FMR1 gene on the X 
chromosome. The normal FMR1 allele may contain up to 45 CGG repeats and is 
stably inherited, however the intermediate mutant allele (45 to 54 repeats) may 
show instability upon transmission (ACMG practice guidelines; 2005 (37)). 
The premutation (55-200 CGG repeats) can expand to a larger premutation or to 
a full mutation harboring >200 CGG repeats. Such a full mutation causes hyper- 
methylation and subsequent silencing of the FMR1 gene and loss of fragile X
18
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related mental retardation protein (FMRP). This loss of FMRP causes fragile X 
syndrome (FXS; OMIM 309550), the most common heritable cause of mental 
retardation. Individuals with FXS also have apparent facial features such as large 
protruding ears and a long face with a prominent forehead. Behavioral and social 
problems like autism and attention deficit disorder are also frequently seen in FXS 
patients. Both males and females can be affected by the fragile X syndrome, 
though females are usually more mildly affected.
In every female cell one of the two X chromosomes is inactivated to ensure 
dosage compensation. Normally, this inactivation is achieved at random in every 
cell leading to an overall 50% activity of both alleles within tissues and organs. 
However, due to non-random X chromosome inactivation (XCI) females who have 
a FMR1 full mutation may still form FMRP with a resulting effect on the severity of 
the phenotype. Only one third of the females who carry the abnormal gene suffer 
from a decreased intelligence. In general, these females have also less obvious 
physical characteristics.
The FMR1 premutation
Several population-based studies have shown that 1 in every 250-300 women in 
the general population is carrier of the FMR1 premutation (40-42). At first the only 
clinical association with the premutation was the risk of CGG repeat expansion to 
a full mutation when transmitted to the offspring. In the last decade a progressive 
neurodegenerative disorder called fragile X associated tremor and ataxia 
syndrome (FXTAS), mostly seen in males (50% of males aged 70-90 years), but 
also rarely seen in females (43), became apparent in FMR1 premutation carriers, 
besides the above described FXPOI. In these disorders not lack of the FMRP but, 
instead, excessive amounts of FMR1 mRNA resulting from the larger CGG repeat 
length appears to be important in their pathogenesis. For FXTAS this hypothesis 
has been tested extensively in animal models (44;45) and brain tissue from a 
FXTAS affected male patient indeed showed high levels of mRNA and inclusion 
bodies (46). However, for FXPOI the role of mRNA has not sufficiently been 
assessed (47;48), and whether or not FXPOI and FXTAS are caused by similar 
pathogenic mechanism still remains to be determined. As yet, the etiology of 
FXPOI may best be explained by either of two basic mechanisms: (i) failure to 
form an adequate initial ovarian pool of oocytes because of migration failure of 
the germ cells or because of defective mitotic activity of oogonia, or (ii) defects 
leading to exaggerated attrition of the normally acquired initial pool of oocytes.
19
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Incomplete penetrance of FXPOI
Not all female premutation carriers develop POI, and only approximately 20% of 
the carriers have amenorrhea for a prolonged period or indefinite before they 
become 40 years of age. Allen et al. (47;49) explored various molecular and 
reproductive factors for their association with the occurrence of FXPOI and found 
that CGG repeat length is an important factor in the development of FXPOI. A 
non-linear association of repeat length with the development of POI was first 
described by Sullivan et al. (37) followed by Ennis et al. (50) shortly thereafter. 
Odds ratios for FXPOI of 6.9 were reported in women with a low premutation 
range (59-79 CGG repeats) and 25.3 and 16.4 for women with medium (80-99 
CGG repeats) and high (>100) CGG repeat ranges, respectively (37;50). The 
observation that some women with the same CGG repeat size develop POI 
whereas others do not strengthens a multi-factorial nature of FXPOI. Indeed, 
smoking has been shown to decrease menopausal age and, thus, may serve as 
such a factor. No association was found between various autoimmune disorders 
and FXPOI (49;51).
Candidate predictors
To minimize the need for fertility treatment and involuntary childlessness, the early 
identification of women at risk for ovarian insufficiency is desirable. For this early 
identification, genetic and non-genetic factors need to be assessed for their 
association with FXPOI and their putative value as predictors. These predictors 
may include genetic, environmental and reproductive factors, but may also be a 
representation of the effect of both genetic and environmental factors as marker 
for the function or status of the organs of interest: the ovaries.
Genetic factors such as inactivation of the X chromosome carrying the premutation 
allele and the length of the FMR1 CGG repeat may potentially serve as important 
predictors. The FMR1 CGG repeat size is significantly associated with FXPOI (see 
above), indicating that this could be a powerful predictor. High correlations 
between menopausal age of first degree relatives in the general population (52) 
and evidence for genetic contributions to the severity of FXPOI imply that 
menopause of first degree relatives might also contribute to the prediction of 
FXPOI. Candidate predictors from environmental origin, such as smoking (see 
above) and body-mass index (BMI) (53) also require validation. Besides 
environmental factors, also reproductive factors need to be assessed as predictor. 
Although the age at menarche, the use of OCs and parity have been associated 
with a later or earlier menopausal age in the general population (54-57), further 
analyses are needed to assess their predictive power for a premutation carrier 
population. Of all known markers for ovarian function and reserve, the AMH level 
seems to be an early indicator of diminished ovarian reserve and to be associated
20
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with age at menopause in the general population (56). Interestingly, AMH has also 
been associated with ovarian reserve in FMR1 premutation carriers (32), which 
turns it into a candidate predictor for FXPOI as well.
Counseling for premutation carriers
Female premutation carriers urgently need genetic and reproductive counseling.
First, because of their risk of having a child with fragile X syndrome and to inform 
them about the possibility of prenatal testing or pre-implantation genetic diagnosis 
(PGD). Second, because of their risk to develop FXPOI, which can seriously 
hamper reproduction, particularly since the increase in postponement of 
childbearing in the general population during the last decades. An additional 
problem for young women with a FMR1 premutation may be that the possibility to 
use PGD is limited. To qualify for PGD in the Netherlands, FSH serum levels must 
be within the normal range (<15 IU/l), whereas FMR1 premutation carriers already 
have elevated FSH levels while having a regular menstrual cycle (59). Also, FMR1 
premutation carriers with <100 CGG repeats suffer from impaired ovarian 
response to hormone stimulations and a decreased fertilization rate (60).
Premutation carriers need administration of significantly more FSH to yield the 
same number of oocytes as compared to overall assisted reproductive technology 
{g } (ART) patients (61). {g }
These difficulties call for research not only on the pathogenic mechanisms, but 
also on the clinical aspects and the ability to identify FMR1 premutation carriers 
who have a high risk of developing FXPOI. For FXPOI counseling, we are in need 
of better risk estimates of the likelihood of POI based on family history and the 
number of CGG repeats (62). Because the development of a complex trait such 
as FXPOI depends on both genetic and environmental factors (multi-factorial 
disorder), these factors should both be assessed to develop risk estimates.
1.6 Aim and outline of this thesis
The general aim of this thesis was to examine the suitability of genetic, 
environmental and reproductive factors as predictors for FXPOI and, based 
on this information, to develop a prediction model for the age at which FXPOI 
occurs.
To this end, in chapter 2 we evaluated the role of skewed X-chromosome 
inactivation in the development of menopause before the age of 40 years among 
fragile X premutation carriers. In chapter 3 we assessed genetic and environmental 
factors as predictors for FXPOI by their association with age at menopause.
Based on a large epidem iological study among fragile X families and a general 
population cohort, we developed a preliminary prediction model. In chapter 4 we 
assessed the potential of an ovarian reserve marker, anti-Mullerian hormone
21
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(AMH), as a predictor for FXPOI. In order to assess this potential we developed 
standardized AMH values for age and FMR1 premutation status and assessed 
intra-individual variation of this variable. To identify novel genes involved in the 
development of FXPOI we performed linkage analysis in a family with excessive 
FXPOI. In chapter 5 we report a candidate locus that may act as a modifier and, 
thus, may serve as a useful predictor. Not only FXPOI, but also other non-syndromal 
forms of familial POI may have a genetic origin. To identify novel genes associated 
with this form of ovarian insufficiency, we performed in chapter 6 a linkage 
analysis in a large Dutch family with hereditary POI in two generations. This 
analysis yielded a locus on chromosome 3. A general discussion and an outline 
for future research are provided in chapter 7.
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X chromosome inactivation does not define 
the development of premature ovarian failure 
in fragile X premutation carriers
#Chapter 2
Abstract
Background: Since only 20% of female fragile X premutation carriers develop 
premature ovarian failure (POF, i.e. amenorrhea before age of 40 years), and 
since X chromosome inactivation (XCI) determines the phenotypic severity of full 
mutation women, we reasoned that the development of POF in fragile X premutation 
carriers could be due to skewed XCI (XCI ratio >80:20).
Methods: To determine inactivation ratios and activities of the premutations, 
inactivation patterns were assessed in peripheral blood samples from 101 fragile 
X premutation carriers (mean age 47.1 years, range 12-72) through analysis of the 
AR and FMR1 loci, respectively. In addition, AR inactivation patterns were assessed 
in peripheral blood samples from 25 women with idiopathic POF (mean age 31.7 
years, range 19-48). We addressed the association between age and skewed XCI 
because older women are prone to XCI skewness.
Results: The median XCI ratios were 68% for premutation carriers with POF 
(N = 37), 67% for premutation carriers w ithout POF (N = 64) and 61% for women 
with idiopathic POF (N=25). The incidence of skewing was similar in all groups, 
i.e., 7 of 37 (18.9%) in premutation carriers with POF, 11 of 64 (17.2%) in premutation 
carriers without POF, and 3 of 25 (12%) in women with idiopathic POF. There was 
good concordance between inactivation ratios at the two loci tested in 62 
premutation carriers (intraclass correlation coefficient =0.86; p<0.01). No 
age-specific skewing was observed.
Conclusion: Skewed XCI and activity of the premutation are not associated with 
POF in fragile X premutation carriers.
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Introduction
The fragile X syndrome (MIM 309550) is caused by expansion of a trinucleotide 
(CGG) repeat in the 5 ’ untranslated region of the fragile X mental retardation 
(FMR1) gene (1). Subsequent hypermethylation leads to transcriptional silencing 
of the gene, which results in a deficiency for the fragile X mental retardation 
protein (FMRP) (2;3). Typical clinical features of affected males are mental 
retardation, large protruding ears, macroorchidism and behavioral abnormalities. 
Males are more severely affected than females. The commonly used classification 
of repeat sizes distinguishes four different groups (4). Normally, the 5’ untranslated 
region of the fragile X mental retardation (FMR1) gene contains less than 50 CGG 
repeats. These repeats are stably inherited. Alleles with CGG repeats in the 
intermediate range between normal and premutation (50 to 58 repeats) may show 
some instability upon maternal and paternal transmission. Repeat sizes of 59-200 
trinucleotides are considered as premutations. These premutations are meiotically 
unstable and can expand to full mutations of at least 200 CGG repeats when 
transmitted by females only.
It has been well documented that female carriers of the fragile X premutation have 
an increased risk for development of premature ovarian failure (POF) (5-7), a 
condition in which women experience spontaneous secondary hypergonadotro­
pic amenorrhea prior to the age of 40 years.
Since only 20% of female premutation carriers develop POF (6;7), and since X 
chromosome inactivation (XCI) determines the phenotypic severity of full mutation 
women, we reasoned that the development of POF in fragile X premutation 
carriers could be due to the presence of skewed XCI. Theoretically, normal 
females should exhibit a random (~50:50) inactivation of the maternal and 
paternal X chromosomes. However, several studies have indicated that, depending 
on age, non-random XCI may be a common event in healthy females (8;9). 
Besides age, XCI patterns may be different in various tissues (10-12). A ratio of > 
80:20 has now been denoted as a threshold for defining a skewed phenotype, 
occurring in approximately 14% of healthy adult females (13).
Recently, several studies were performed to assess whether XCI might be a 
relevant factor in idiopathic POF development. Whereas Sato et al. (14) observed 
more extremely skewed XCI in 43 women with POF, Bione et al. (15), Bretherick et 
al. (16) and Yoon et al. (17) failed to find any significant differences in the degree 
and frequency of skewed XCI in extended POF cohorts (59-151 women with POF). 
Therefore, an association between XCI and idiopathic POF seems unlikely. In 
women with a defect on the X chromosome, however, XCI may contribute to the 
development of a specific phenotype, i.e., in FMR1 premutation carriers with POF, 
unlike in females with idiopathic POF, skewed XCI may act as such.
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So far, XCI studies aimed at defining a relationship between premutation carriers 
and POF have remained contradictory, mainly due to the small cohorts studied. 
Bodega et al. (18) reported that the allele carrying the premutation was active in 
tw ice as many POF cases as compared to matched healthy premutation carriers. 
Others (19-21) were unable to confirm these results and implied that XCI patterns 
are random and insignificant for POF development.
Also, literature has remained ambivalent about a possible positive correlation 
between skewed XCI and age. Whereas a significant difference in percentage of 
skewed XCI between young healthy women (aged <25 and 28-32, respectively) 
and healthy women aged 60 and older has been reported by some (10;22), others 
failed to observe a significant augmentation in the amount of skewing with age, 
even above the age of 60 years (8;23).
The most commonly used assay for the determination of XCI patterns is based on 
a highly polymorphic DNA repeat present in the androgen receptor (AR) gene on 
the X chromosome (24), but polymorphisms in other X chromosomal loci have 
also been used, i.e., in ZNF261 (25), FMR1 and PGK (26). Since discrepancies 
have been reported in 6.2-12% of women by using either one of these assays 
(22;25), we have opted for the employment of two alternative approaches to 
determine XCI patterns in premutation carriers based on (i) the previously 
mentioned polymorphic DNA repeat in the AR gene and (ii) the CGG repeat in the 
FMR1 locus, which is the primary site of interest. To test our hypothesis, i.e., is 
there a relationship between POF and XCI, we investigated peripheral blood 
samples from premutation carriers for inactivation patterns through analysis of 
both the AR and FMR1 loci. Subsequently, we compared the inactivation patterns 
of female premutation carriers with POF to those of female premutation carriers 
without POF and women with idiopathic POF. In addition, we determined the 
concordance in XCI status at the two X chromosomal loci investigated in female 
premutation carriers.
Materials and methods
Premature ovarian failure (POF) was defined as spontaneous menopause at age 
<40 years. In this study we defined menopause as amenorrhea for at least 6 
months with FSH levels above 40 IU per liter or as spontaneous cessation of 
menstruation for older women. Spontaneous cessation of menstruation does not 
apply to women with termination resulting from hysterectomy, bilateral 
oophorectomy, chemotherapy, radiotherapy, or ablative medication, and these 
women were consequently excluded.
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Subjects
The present study includes 142 females. All individuals were tested in a routine 
DNA diagnostic setting for fragile X repeat length, either because the fragile X 
syndrome segregated within the family, or because the females themselves 
suffered from POF. All 142 females were interviewed for age at menopause, family 
history of POF and congenital abnormalities, health and fertility status, pregnancies 
and onset of menarche. All females in whom POF could be established reliably 
had secondary amenorrhea before the age of 40 years and exhibited a normal 
karyotype.
Heterozygosity for the androgen receptor (AR) polymorphism (CAG)n was 
detected in 126 of the 142 females included, which means that these cases were 
informative for XCI pattern analyses. This cohort of 126 females consisted of two 
different groups: one group comprising 101 fragile X premutation carriers from 68 
families which, based on the parent of origin of the premutation, could be 
subdivided into paternally inherited (N=67), maternally inherited (N=27) and 
unknown (N=7) cases. Among the 101 premutation carriers (mean age 47.1 years, 
range 12-72), twelve were carriers of an allele with a normal repeat length in 
addition to an allele that was mosaic within the premutation range. These women 
with mosaicism were included in all analyses, except the repeat length analyses. 
The second group consisted of 25 females (mean age 31.7 years, range 19-48) 
with a normal FMR1 CGG repeat length and an unknown cause of POF (i.e., 
idiopathic POF). The latter group was added as a control group to assess whether 
premutation carriers with POF exhibit different methylation patterns compared to 
women with idiopathic POF. These 25 females were referred independently to our 
clinic for POF and are not related to the premutation carriers, or to each other. The 
control group of women considered as having idiopathic POF were all healthy, 
w ithout endocrine deficiencies: i.e. thyroid function, testosterone levels and 
cortisol levels, w ithout family history of congenital abnormities, and only two 
women had one first- or second-degree relative with POF.
The three groups had comparable ages at menarche, but the women with 
idiopathic POF were significantly younger at development of POF and as a 
consequence, had fewer pregnancies, children and miscarriages (See Table 1). 
The difference in number of pregnancies and children can be explained by the 
fact that the premutation carriers had children at an earlier age and developed 
POF at an older age; thus more children were born before they developed POF.
X chromosome inactivation analysis
XCI patterns were determined using two methods based on (i) the presence of a 
polymorphic repeat within the 5 ’end of the AR gene and (ii) the presence of a 
(CGG)n repeat within the FMR1 locus. Analysis of the AR repeat was performed
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Table 1 Reproductive characteristics of the population
Premutation
POF
(N=37)
Premutation 
no POF 
(N = 64)
Idiopathic
POF
(N=25)
p-value
Mean age at menarche (years) ±SD 13.8± 1.6 13.2± 1.2 13.1± 1.7 0.221
Mean age at menopause (years) ±SD 34.6± 4.5 48.0± 3.7a 29.5± 5.2 < 0.0012
Women with pregnancy 28/37 (76%) 61/64 (95%) 6/25 (24%) < 0.0013
Mean no. o f children per woman 2.5 2.5 1.3 0.071
Women with miscarriages 7/25 (28%)b 19/57(33%)b 1/6 (17%) 0.603
No. of twin pregnancies 0 0 0
Premature ovarian failure (POF) defined as spontaneous menopause at age <40 years. 
p-values with respect to differences between groups based on: linear mixed models with random 
family effect ; 2: linear mixed model analysis comparing premutation women with POF to idiopathic 
POF taking within-family correlations into account; 3: GEE analysis taking within-family correlations into 
account; *: not included in calculation p-value. #: information on miscarriages was unavailable for 
7 premutation carriers.
for all females in this study. In this method, 1 j g  of DNA extracted from peripheral 
blood cells was digested with BamHI and the methylation-sensitive enzyme Hpall. 
PCR amplification of the AR alleles was performed with a fluorescein (FAM)-labeled 
reverse primer (primer sequences and PCR conditions available upon request). 
Fragment lengths were measured using an ABI PRISM 3730 DNA Analyser 
(Applied Biosystems) and quantified using ABI PRISM Genemapper Analysis 
Software v4.0 (Applied biosystems). In the second method, methylation patterns 
at the FMR1 locus were determined, again using DNA extracted from peripheral 
blood cells. Southern blot analyses were performed after EcoRI/EagI double 
digestion followed by hybridization with probe pAO365 (the PstI fragment from 
the 5’UTR of the FMR1 gene that contains the (CGG)n repeat), as shown in Figure 1. 
For half of the premutation carriers (with or w ithout skewed XCI based on the first 
method) Southern blot analyses were performed for DNA diagnostic purposes 
prior to this study. In addition, for all women with skewed XCI based on the first 
method and without previous Southern blot results, Southern blot analysis was 
performed. To quantify the methylation levels of the FMR1 alleles, autoradiograms 
were scanned on a laser densitometer (GeneSnap version 7.05.02, SynGene) and 
the ratios were determined between the two peaks representing the normal allele 
and the premutation allele at the active X chromosome (GeneTools V4 analysis 
software, SynGene). Similar comparisons at the inactive X chromosome were not
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Figure 1 Determining X chromosome inactivation (XCI) patterns at the FMR1 
locus
Southern blot analysis was performed using an EcoRI/EagI double digest, resulting in a 5.2 kb band for 
the inactive X chromosome and a 2.8 kb band for the active X chromosome. The normal allele (N) and 
the premutation allele (P) are shown. In this example the first lane contains DNA of a patient in whom the 
premutation allele is mainly active. The other lanes show patients in whom both alleles are equally active.
feasible due to long fragment lengths prohibiting a clear distinction between the 
normal and the premutation allele.
Outcome measures and statistical analysis
In this study two outcome measures were used: XCI ratio and premutation activity. 
XCI ratio was defined as the ratio of activity of both alleles at the AR locus, 
irrespective of whether the normal or the premutated allele was located on the 
active or inactive X chromosome. A generally accepted definition of skewed XCI 
using a cut-off point of > 80:20 (22;27) was used. In cases with skewed XCI, the 
direction of skewing was determined by assigning the highest number of the XCI 
ratio to the FMR1 allele (premutation or normal) with the most intense band on the 
Southern blot.
The premutation activity was determined by Southern blot analysis and defined 
as the percent rate of the premutation peak on the active X chromosome in
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relation to the sum of the normal peak and the premutation peak. To compare the 
XCI ratios and the premutation activities taking correlations within families into 
account, linear mixed models were used in case of continuous outcomes and 
generalized estimating equations (GEE) models in case of binary outcomes. The 
association between age and skewed XCI per subgroup was studied using 
regression coefficients, representing slopes, resulting from linear mixed models. 
To compare the premutation activity based on methylation patterns at the AR 
locus with methylation patterns at the FMR1 locus, we used the intraclass 
correlation coefficient (ICC).
Analyses were performed using the Statistical Package for Social Sciences 
software (SPSS), version 16.0. Analyses using linear mixed models or GEE were 
carried out with Statistical Analysis Software (SAS), version 8.2. Significance was 
set at p  <0.05.
Results
Within the cohort of 101 informative fragile X premutation carriers, 37 had 
experienced POF, i.e., occurrence of menopause <40 years of age, whereas 
menopause in the other 64 women occurred above 40 years of age. The control 
group consisted of 25 women considered to have idiopathic POF.
Here, we compared the XCI patterns of the 37 POF-positive premutation carriers 
to those of the 64 POF-negative premutation carriers and, in addition, to those of 
25 women with idiopathic POF. We also compared the test results obtained from 
two loci (AR and FMR1) in 62 premutation carriers.
Similar skewing in premutation carriers with and without POF
The mean age of the premutation carriers included in this study was 45.9 years 
for those with POF and 47.8 years for those without POF. The premutation repeat 
length of the women with POF varied between 62 and 101 and of the women 
without POF between 56 and 137. The median XCI ratio was 68% for premutation 
carriers with POF and 67% for premutation carriers without POF. The incidence of 
skewed XCI (ratio of > 80:20) was similar in both groups: 7 of 37 (18.9%) 
premutation carriers with POF and 11 of 64 (17.2%) premutation carriers without 
POF (Figure 2). Only 4 of the women with skewed XCI were related. They belonged 
to 2 different families. In both families, one female was a premutation carrier with 
POF and the other one a carrier without POF.
The contribution of the premutation on the active allele was determined by 
Southern blot analysis. By doing so, we found that in 3 out of 7 women with 
skewed XCI and POF the premutation was mainly active. Five of the 11 women
34
#
2#
XCI does not define the development of POF
#
Figure 2 Distribution of XCI at AR locus in premutation carriers with and
without POF and in women with idiopathic POF
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with skewed XCI without POF showed preferential activation of the premutation. 
The median XCI ratio in 25 women with POF and a normal repeat length (idiopathic 
POF) was 61%, i.e., not statistically different from premutation carriers with and 
without POF (linear mixed models; p  = 0.33). The incidence of skewing (> 80:20) 
in idiopathic POF women was lower than that observed in premutation carriers, 
i.e., 12.0% and 17.8%, respectively (p = 0.32, GEE analysis). To assess the 
association between age and skewed XCI, the slopes of fitted regression lines 
were determined, i.e.: premutation carriers with POF, slope = 0.04; premutation 
carriers without POF, slope = 0.08; idiopathic POF, slope = -0.29. For comparison 
of the slopes we used linear mixed models (p =  0.78, 0.55 and 0.47, respectively), 
i.e., no augmentation of skewing with age was observed (see Figure 3).
XCI is concordant between the AR  and FMR1 loci
To compare the two XCI methods used, the activity of the premutation in 62 
women (18 with XCI ratio > 80:20 and 44 with random XCI ratios) was determined
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based on Southern blot analysis. This resulted in comparable mean premutation 
activities for both methods: 54.5% (AR) versus 54.1% (FMR1), p  =  0.87 (paired 
t-test) for premutation carriers with POF, and 51.3% (AR) versus 52.8% (FMR1), 
p  =  0.45 (paired t-test) for premutation carriers without POF. The intraclass 
correlation coefficient (ICC) was 0.86. From these results we conclude that there 
is a good concordance between the two XCI methods used.
Figure 3 Scatter plot of XCI ratios at AR locus and age in premutation
carriers with and without POF and in women with idiopathic POF
Age at bloodsample (years)
Boundary of skewed XCI, defined as inactivation ratio >80:20: ----------
*  : premutation carrier with POF; fitted regression line slope = 0.04, p = 0.78
o : premutation carrier w ithout POF; fitted regression line slope = 0.08, p = 0.55 
a  : woman with idiopathic POF; fitted regression line slope = -0.29, p = 0.47 
p-values: based on linear mixed model analyses
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Discussion
The aim of the present study was to address the question of whether female 
carriers of the fragile X premutation with POF exhibit a skewed XCI compared to 
premutation carriers without POF. By using two assays employing known 
polymorphisms within the AR and the FMR1 loci, we found that the amount of 
skewed XCI did not differ significantly between women with and without POF. 
Also, comparison of the activity of the premutation in women with and without 
POF showed no significant difference. Based on the data presented here, we 
conclude that skewed XCI in fragile X syndrome premutation carriers is not 
associated with POF. The size of our sample made it possible to detect an 
enhancement of XCI ratios of 23% or more.
XCI is a complex phenomenon that appears to be affected by various factors, 
such as population-specific, age-dependent and hereditary factors. In addition, 
XCI ratios may vary by tissue type within one individual. Here, we used stringent 
patient inclusion criteria to minimize the effect of population-specific factors, i.e., 
carriers w ithout POF had to be over age 40 years at the time of interview to reliably 
exclude POF.
Hatakeyema et al. (8), Busque et al. (22) and Sharp et al. (10) assessed XCI ratios 
in neonates and/or young women (<32 years) and women aged above 60 years. 
Since our population consisted of only 16 women with age above 60 years and 17 
women younger than 31 years, our current cohort is too small to reliably assess 
age-dependent effects.
For all our analyses, we used DNA extracted from peripheral blood cells. It should 
be noted, however, that XCI patterns may differ in different tissues (11). In contrast, 
others have shown a substantial correlation between multiple tissues (10;12). 
Bittel et al. (11) examined XCI patterns in ovarian tissue and blood cells and found 
that XCI ratios in ovarian tissue differ from blood cells, but that in 3 of 4 women, 
the XCI percents were very similar. The woman with large difference in XCI was 61 
years. However excluding women above the age of 60 years did not alter our 
results (data not shown).
Previously, Naumova et al. (9) suggested that XCI phenotypes may be hereditary, 
whereas Boldus et al. (12), who examined concordance between more than 400 
mother-daughter pairs, failed to obtain any evidence for a genetic component to 
skewing. Since some of our premutation carriers were related, we corrected for 
family correlations by using GEE analysis for correlated data and linear mixed 
models. This correction did not affect the prior conclusions (see corresponding 
p-values given in Table 2).
One of the FMRI-related risk factors for the development of POF is the (CGG)n 
repeat length. Repeat sizes in the medium premutation range (80-99 repeats)
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Table 2 X chromosome inactivation (XCI) ratios at the AR and FMR1 loci and 
the activity of the premutation
Number of 
patients
Mean age (years) 
±SD
Mean repeat length 
±SD
Premutation POF 37 45.9±13.2 81 ±10.8
Premutation no POF 64 47.8±11.6 83±18.5
Idiopathic POF 25 31.7± 6.6 31.6 ± 4.1*
Total 126 44.0±12.9 NA
p-value 0.441
p-values with respect to differences between groups based on: 1: linear mixed model analysis taking within 
family correlations into account comparing premutation carriers not idiopathic POF group;
2: linear mixed model analysis of logarithmic transformed XCI values, taking within family correlations into account;
3 :GEE analysis of correlated dichotomous outcome taking within family correlations into account;
4 :linear mixed model analysis taking within family correlations into account;
*: not included in calculation p-value; NA: not applicable.
have been associated with the highest risk for POF (28). We considered a possible 
effect of activity of the premutation and repeat length on POF, but failed to find 
such an association. We were also unable to confirm that repeat sizes of 80-99 
repeats were associated with the highest risk of POF. We found the highest 
percentage of POF in the low premutation group (60-79 repeats):16/33 (48%).
In the premutation range (80-99 repeats) the percentage of women with POF was 
33% (14/42). Previously, we have suggested another FMR1 -related risk factor for 
the development of POF, i.e., a paternally inherited premutation (PIP) (6). Others, 
however, were unable to confirm such an effect (29-31). Here we found that the 
methylation patterns did not differ between paternally and maternally inherited 
premutations (MIP), i.e., median XCI ratios of 68% for PIP and 64% for MIP and 
mean activities of the premutation of 68% for PIP and 65% for MIP.
We used two independent methods to determine XCI ratios, i.e., a well-established 
polymorphic androgen receptor (AR) gene assay and a second assay employing 
a polymorphism within the FMR1 locus itself. In five women major discrepancies 
were observed between the two methods: XCI ratios were skewed with one 
method and random with the other, In one case (ratio 15 versus 38) one of the 
peaks was overrated by the imager due to oversaturated bands, the other 4 
discrepancies remain unexplained, but the prevalence of discrepancies in XCI 
ratios is comparable to that previously reported (25).
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Median XCI ratio (%) 
(P25;P75)
Skewed XCI 
(>80:20)
N (%)
Mean premutation 
activity AR (%) 
±SD
Mean premutation 
activity FMR1 (%) 
±SD
68 (56;78) 7 (19%) 54.5±23.2 54.1±26.3
67 (57;75) 11 (17%) 51.3±25.8 52.9±25.8
61 (54;71) 3 (12%) NA NA
66 (55;74) 21 (17%) 52.7±24.5 53.4±25.8
0.332 0.493 0.754 0.954
Our method of rating XCI ratios at the FMR1 locus seems to slightly overestimate 
the actual ratios. This overestimation may be explained by the limited capacity of 
the imager used to discrim inate between the two active alleles when the CGG 
repeat length of the premutation is in the lower range (59-65) and/or the normal 
allele is in the high normal to intermediate range (40-58). Another explanation 
may be a partial breakdown of genomic DNA, which could hamper the detection 
of larger DNA fragments. In such a case, small DNA fragments can still be 
amplified by PCR (as used in the detection of the AR alleles), but upon Southern 
blot analysis, an overestimation of small fragments (i.e. normal alleles) compared 
to large (premutated) fragments may result.
After correcting for possible confounders wherever possible, we did not find a 
correlation between XCI ratios and POF, nor between XCI ratios and age. Taken 
together, we conclude that skewed XCI is not linked to the clinical manifestation 
of POF in fragile X premutation carriers.
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Abstract
Purpose: Women who carry a FMR1 premutation are at risk for fragile X-associated 
primary ovarian insufficiency (FXPOI) and should be counseled for a potentially 
reduced fertility. Multiple factors can affect the age of onset and severity of FXPOI. 
Here, we assessed the predictive power of several factors with menopausal age, 
a surrogate measure of onset of FXPOI.
Methods: Genetic, environmental and reproductive factors were analysed by Cox 
proportional hazard models in 1,068 women, 385 of fragile X families ascertained 
through the Nijmegen study and 683 of fragile X families or general population 
families ascertained through the Atlanta study.
Results: The highest association with menopausal age among FMR1 premutation 
carriers was found for risk index by CGG repeat size (HR 1.43) and smoking (HR 
1.34). Women from the Nijmegen cohort showed an overall lower age at 
menopause onset, for which a correction was made. A prediction model based 
on these two parameters, mean menopausal age of first degree relatives with the 
same mutation status and the correction for ascertainment site, estimated the 
probability of becoming postmenopausal for premutation carriers, with a margin 
of 7-10%.
Conclusion: We conclude that this model serves as a first step towards clinical 
application of FXPOI prediction.
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Introduction
In the early 1990s, premature ovarian failure (POF), or cessation of menses prior 
to the age of 40 years, was noted among heterozygous carriers of the FMR1 
premutation (1;2). Additional studies showed that the risk of POF was almost 
exclusively seen in females carrying a premutation in the FMR1 gene and that 
approximately 20% of these carriers had POF (3;4). To better denote the complete 
spectrum of this disorder, including altered menstrual cycles, altered hormone 
profiles, infertility and intermittent ovarian function, this premutation disorder was 
renamed as Fragile X-associated Primary Ovarian Insufficiency (FXPOI) (5), 
defined as amenorrhea for at least 4 months and two serum FSH levels above 40 
IU/l.
The FMR1 premutation represents an expansion of a trinucleotide (CGG) repeat 
in the 5 ’ untranslated region of the fragile X mental retardation (FMR1) gene (6). 
Based on the number of repeats present and their instability when passed from 
one generation to the next, four types of FMR1 alleles can be distinguished: 1) a 
normal allele with <45 repeats, which is stably inherited; 2) an intermediate 
mutant allele with 45 to 54 repeats, which may show instability upon maternal or 
paternal transmission; 3) a premutation allele with 55 to 200 repeats, which can 
expand to a full mutation within one generation; and 4) a full mutation allele with 
at least 200 CGG repeats (ACMG practice guidelines; 2007), which results in an 
intellectual and developmental disability syndrome, the fragile X syndrome (7). 
Women who carry the premutation should be informed, not only about their risk 
for having a child with fragile X syndrome, but also about their potential risk for 
FXPOI, as symptoms include infertility, early cessation of menses and early 
exposure to estrogen deficiency.
In the general population menopause ranges from ages 40 to 60 years with a 
mean of 51 years (8) and appears to be modulated by both environmental and 
genetic factors (9-12). As yet, Allen et al. (13) showed that smoking led to an 
earlier age at menopause among premutation carriers, however the association 
of menopausal age with other factors, such as menarche and parity is still a 
matter of debate. Although environmental and reproductive factors both contribute 
to variance in age at menopause, genetic factors seem to act as superior 
predictors for age at menopause (12). The size of the FMR1 CGG repeat is a major 
risk factor for FXPOI. Within the FMR1 premutation range of 55 to 200 repeats, 
Allen et al. (13) and Sullivan et al. (14) identified high risk alleles of 80-99 repeats. 
This non-linear association was subsequently confirmed by others (15;16). The 
subdivision of the premutation ranges used by Allen et al. (13) into low (55-79 
repeats), medium (80-99 repeats), and high (100-200 repeats) has, however, 
been based on the risk to expand to a full mutation (17), and any detailed
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information on high risk alleles for FXPOI is therefore still lacking. Here, we have 
developed an integrative model that allows the prediction of the risk to develop 
FXPOI in individual premutation carriers. Such a model would serve as an 
excellent adjunct to current fertility counseling modalities and the clinical 
intervention in premutation carriers.
Methods
Study population
The study cohort is comprised of participants ascertained through two centers, 
the Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands 
(Nijmegen cohort) and the Emory University Department of Human Genetics, 
Atlanta, USA (Atlanta cohort). The Dutch study was approved by the Institutional 
Review Board of the Radboud University Nijmegen Medical Centre. The Atlanta 
protocol and consent forms were approved by the Institutional Review Board at 
Emory University.
All fragile X families that were diagnosed at the Department of Human Genetics 
Nijmegen between 1985 and 2008 were ascertained for this study. All female 
relatives of a proband at age 35 years or older were approached to participate in 
this study, and asked to complete a general health and reproductive history 
questionnaire. A detailed description of the study population is depicted in Figure 1. 
The Atlanta cohort was comprised of women who were recruited through the 
Emory Study of Adult Learning and Reproduction. Ascertainment protocols have 
been described in detail by Sullivan et al. (14).
Data collection
Reproductive history questionnaire
For both studies comparable questionnaires on general health and reproduction 
were administered by phone, in written format, or through an internet survey. Both 
reproductive questionnaires gathered information on time since last menstrual 
period, cause for cessation of menstrual periods (for example menopause, 
hormones, surgery), age at last period, age at start hormone use -  hormone 
replacement therapy (HRT) and oral contraceptives (OC), time period of hormone 
use, and current hormone use.
Definition of age at menopause
Age at menopause was used as a surrogate for severity for FXPOI and was 
defined as amenorrhea for more than 1 year due to natural menopause. Ages at 
menopause for all women with other reasons than natural menopause for
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cessation of menstrual cycles were “censored”. For women who had their last 
period due to surgery (e.g. hysterectomy or oophorectomy), chemotherapy, 
radiation or pregnancy, menopausal age was censored at age at last period. 
Women who still had menstrual cycles (last period < 1 year) without current 
hormone use were censored at age at interview. Women with recent periods and 
current hormone use were censored at age when hormone use was started.
FMR1 CGG repeat size measurement
From the participants included in the Dutch study, DNA was extracted from 
peripheral blood cells. PCR amplification of the FMR1 alleles was performed 
using 6-carboxyfluorescein-labeled reverse primers as described by Fu et al. 
(18). PCR conditions are available upon request. Fragment lengths were measured 
using an ABI prism 3730 DNA Analyser Applied Biosystems) and quantified using 
ABI prism Genemapper Analysis Software v4.0 (Applied Biosystems) up to 1 or 2 
repeats accurate until 130 to 140 repeats. From the women participating through 
Atlanta, DNA was extracted from buccal samples or peripheral blood cells using 
Qiagen QiAmp DNA Blood Mini Kit. FMR1 CGG repeat sizes were determined by 
a fluorescent-sequencer method as described by Sullivan et al. (14), with the 
same accuracy as the Dutch method, up to 100 repeats and with an inaccuracy 
of 5-10 repeats for repeat sizes 100-140.
Statistical analysis
The data were analyzed using age at menopause, a surrogate for FXPOI, as 
outcome variable in Cox proportional hazards models. To this end, the time origin 
was set at the age of 25 years and the time from 25 years to start menopause was 
considered as the time to event. To adjust for the correlation among outcomes 
within the same family we applied robust estimates each time we made use of a 
Cox regression mode (19). Analyses were performed separately for FMR1 
premutation carriers and non-carriers.
Construction of risk index for earlier menopause based on FMR1 CGG repeat size
Cox regression with robust estimations were used to determine risk estimates for 
menopause at a younger age based on FMR1 CGG repeat size. A reference 
region based on most common repeat sizes encountered in the general population 
was defined to be 28-33 repeats (18;20). For repeat sizes 20-27 and 34 repeats to 
100 repeats, a set of moving windows with a w idth size of 11 repeats was created. 
In case of overlap between w indow and reference region, repeats present in the 
overlap were removed from the window. The menopausal age for subjects within 
a w indow was compared to menopausal age of subjects in the reference region, 
resulting in a w indow-specific hazard ratio, HRr, where the index r refers to the
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central repeat size in the window. To determine these HRs, we applied Cox 
regression with robust estimations. Because repeat size determination of 100-130 
repeats was less accurate for the Atlanta subset, a w ider w indow (+/- 10 repeats) 
around the reported repeat size was used. Since sizes above 130 repeats could 
not be determined with accuracy for either cohort, they were not assessed in this 
hazard risk analysis. To reduce the noise in the resulting HR graph, we 
superimposed a smoothed curve that is fitted to the HRs by repeat scatter plot. 
To this end, we used the LOWESS smoother with smoothing factor = 0.1 (21). The 
resulting variable is referred to as the “ Risk Index by Repeat size”: (RIR) and 
ranged from 1 to 3.6, with 1 indicating similar risk for menopause as women with 
repeat size 28-33 and 3.6 indicating an odds of 3.6 of becoming postmenopausal 
per unit time compared to women with repeat sizes 28-33.
Assessment of putative predictors for menopausal age in premutation carriers
Predictive factors for age at menopause were based on previous studies on 
menopause in general and included smoking, body mass index (BMI), age at 
menarche, oral contraceptives (OC) use and parity (12;22;23). The abundant 
evidence of heritability of menopausal age, and the large additive genetic 
component that Hunter et al. (24) showed to be present after correction for the 
premutation repeat size, required a representation into our putative predictor 
assessment as well. To this end, for each subject the mean age at menopause of 
first degree relatives with the same mutation status (premutation if 55-200 repeats, 
non-carrier if < 54 repeats) was determined. If a subject was lacking a first degree 
relative with the same mutation status and well-defined age at menopause, the 
median age at menopause observed in subjects (well-defined age at menopause) 
of the same premutation status, 44 years for carriers and 50 years for non-carriers, 
was employed. Because this study comprises participants from two separate 
studies from different centers, we also considered ascertainment location as a 
possible relevant explanatory variable. Putative predictors were assessed as 
continuous variables, except for smoking and OC use, which were dichotomized 
for ever smoking or ever OC use. As a first step in the modeling process we 
assessed various potential predictors for menopausal age using univariate Cox 
models.
Modeling process and validation
For model building, backward selection was applied, starting with the set of 
variables that showed significance in the univariate analyses. For each potential 
predictor the proportional hazard assumption was determined by inspecting plots 
of weighted Schoenfeld residuals against age at menopause (25). The appropriate 
functional form of continuous predictors was checked using martingale residuals
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as described by Therneau et al. (26). To assess the fit of each resulting model, the 
subjects were divided in three tertile groups based on their values of the linear 
part of the Cox regression model. For each tertile the Kaplan-Meier curve and the 
mean of the predicted Cox survival curves were computed. A perfect fit should 
give comparable curves for each tertile. Both resulting Cox models were validated 
using Efron’s optimism bootstrap to estimate the optim ism in R2 and the 
concordance index c, to quantify the over-fitting and to assess the calibration 
needed (27).
Results
Delineation of the study populations
In total 1,575 women were ascertained in the original studies, 537 from the 
Nijmegen cohort and 1,038 from the Atlanta cohort. Approximately 90% of them 
were Caucasian. Since the number of women from other ethnicities was too small 
to denote an effect, all non-Caucasians were excluded from the initial cohort. To 
correct for age differences in recruitment schemes (Nijmegen recruited 35 years 
and older, Atlanta recruited 18 to 75 years), we selected only women aged 35 -75 
years from both cohorts, resulting in a final study cohort of 1,068 women. The 
characteristics of the final study cohort are shown in Table 1. Women included 
from Nijmegen were older at interview and, thus, had more often reached 
menopause (72%) compared to women included from Atlanta, of whom 34% had 
a well-defined age at menopause. In addition, women from the Nijmegen cohort 
exhibited an overall significant earlier menopausal age. When comparing the 
distribution of FMR1 CGG repeat sizes of the Nijmegen and Atlanta cohorts, no 
difference was seen (p = 0.58, Mann-Whitney U).
Definition of putative predictors
Risk index for earlier menopause based on FMR1 CGG repeat size
To incorporate the non-linear association of repeat size and risk for FXPOI, a risk 
index based on repeat size was developed. In order to explore possible differences 
between the two geographic ascertainment sites, unsmoothed results are 
presented separately. By doing so, both the Nijmegen and Atlanta cohorts 
exhibited no risk for earlier menopause for repeat sizes in the normal or 
intermediate range, as depicted by the 95% confidence interval that includes 
HR=1. In addition, both analyses showed that the risk for earlier menopause 
starts at 64 CGG repeats, at which the lower confidence interval rises above a 
hazard ratio of 1 (Figure 2A and 2B). Also, some differences were seen between 
the two ascertainment sites, i.e., the hazard ratios for 64 repeats or more were
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Table 1 Characteristics of the study population by mutation status
Premutation Non-carriers Total
Nijmegen Atlanta Nijmegen Atlanta
Age at ascertainment (yrs) 56.4 49.6 54.6 52.7 53.0
Age at menopause (yrs)
- Well defined 42.5 43.5 48.3 49.9 45.9
(%) (72%) (34%) (58%) (25%) (42%)
- Censored 41.7 39.0 42.9 42.2 41.0
(%) (28%) (66%) (42%) (75%) (58%)
Menarche (yrs) 13.2 12.4 13.1 12.5 12.7
Parity 2.2 2.1 2.0 2.1 2.1
Ever used hormones (%) 79% 80% 74% 85% 80%
Ever smoking (%) 41% 36% 35% 40% 38%
BMI 24.6 27.0 25.8 27.2 26.5
Ascertainment (N)
- Fragile X family, USA 370 183 51.7%
- General population, USA 3 127 12.2%
- Fragile X family, NL 144 241 36.1%
3
lower for the Ni jmegen study cohort  as for that from Atlanta. Also, with in the 
Nijmegen cohort  the hazard ratios were s ignif icantly  elevated until repeat sizes of 
90, while for the Atlanta cohort  the signif icantly  elevated hazard rat io ’s reached 
100 repeats. Though d ifferences in hazard ratios were seen, the shape of the 
curves was found to be similar, thus allowing pool ing of both datasets. For the 
total s tudy population, a signif icant high risk (lower conf idence band >  1) started 
above 62 repeats, then varied from 1.5 to 3.8 and, finally, becam e non-signif icant 
at 120 repeats (Figure 2C). Repeat sizes of 131-200 (n=21) had a HR of 2.1 (95% 
CI: 1.0 - 4.3), with a signif icant isolated HR-peak at 160 repeats (data not shown). 
The value of the sm oothed Lowess curve was used to assess a predictor to which 
we will refer to as the risk index by repeat size (RIR).
Value of putative predictors
In order to estimate the value of all putative predictors, they were assessed for 
their association with age at m enopause in univariate and multivariate Cox 
analyses with robust estimations in the subgroups  of premutation carriers and 
non-carr iers separately. For all potential predictors no relevant vio la t ion of the
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Figure 2 Hazard ratios (HRs) for earlier menopause by repeat size of the 
largest allele compared to the referent category of 28-33 repeats
repeat size
Panel A depicts hazard ratios (solid line) for the Nijmegen study sample with 95% confidence interval 
(dotted lines). Panel B depicts hazard ratios (solid line) for the Atlanta study sample with 95% confidence 
interval (dotted lines); Panel C depicts the hazard ratios for the total study sample (black dashed line) 
with 95% confidence interval (dotted lines) and superimposed a smoothed curve (solid line), using 
LOWESS smoother with smoothing factor 0.1. The horizontal solid line depicts HR = 1 and the 2 dashed 
lines depict HR=2 and HR=5.
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proport iona l hazards m ode l assum ption was found and all con t inuous variables 
were of the correct functional form. For premutation carriers, the RIR was highly 
associa ted with age at menopause, with an HR of 1.26 for univariate analysis and 
1.43 for multivariate analysis (Table 2). By univariate analysis, two other potential 
predictors showed a s ignif icant association, i.e., mean m enopausa l age of first 
degree relatives with a premutation (HR =  0.97) and sm oking (HR=1.30). Am ong 
non-carriers, except for RIR, the same putative predictors were univariate 
s ignif icantly  associa ted with m enopausa l age: HR =  0.90 for the effect of mean 
m enopausa l age of first degree relatives and HR=1.44 for the effect of smoking. 
The HR<1 for mean age at m enopause am ong first degree relatives suggests  a 
protective factor, or one that helps to increase the age at menopause. The HR>1 
for sm oking indicates a risk factor, or one that reduces the age at menopause. 
Two possib le confounders, age at interview and ascerta inm ent site, were 
s ignif icantly  associated with m enopausa l age in both groups, though only 
ascerta inm ent site held s ignif icance at multivariate levels.
A FXPOI prediction model
A model to generate risk estimates for FXPOI, or m enopausa l age before age 40 
years, for premutation carriers was built upon the s ignif icant predictors based on 
multivariate analysis by backward selection of the predictors with signif icant 
association for univariate analysis, i.e., RIR and sm oking as a predictor for 
m enopausa l age in premutation carriers and ascerta inm ent site (Table 2). For 
comparison, a model for non-carr iers was developed in the same way and 
inc luded mean m enopausa l age of first degree relatives, sm oking and 
ascerta inm ent site. We dec ided to also include mean age at m enopause of first 
degree relatives into the prediction model for the premutation carriers because of 
our f ind ings on heritabil i ty (description of our heritabil i ty analyses and results are 
as Supp lem en t available online) and because we saw an addit ive genetic effect 
in our previous study (24). These m odels  predicted the probabil i ty  of becom ing 
postm enopausa l before 40 years of age with an accuracy of + /-  0.10 among 
premutation carriers and + /-0 .07 for non-carriers.
The high risk profile for premutation carriers consisted of a repeat size w indow  
centered on 80 repeats, smoker, ascerta inm ent site Ni jmegen and young mean 
m enopausa l age of first degree family members, while the low risk profile was 
based on the non-carr ier model and consisted of a repeat size 50, never smoked, 
ascerta inm ent site Atlanta, late mean m enopausa l age of first degree relatives, 
respectively. Accord ing to this model,  w om en with this high risk profile have 38% 
(95%CI: 29 - 47) chance of being m enopausa l before the age of 40 years and, 
thus, are at high risk for FXPOI (Figure 3). The effect of ascerta inment location is 
a 3 to 4 years earlier menopause for the Ni jmegen cohort  as shown for different
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Table 2 Analyses of association of possib le risk factors with age at menopause by Cox proportional hazards model with robust 
estimate for family relations
Premutation Non-carrier
Factors Univariate Multivariate Univariate Multivariate Final m odel
HR p-value HR p-value HR p-value p-value HR p-value HR p-value
Genetic
FMFtl: Risk index by repeat 1.26 <0.001" 1.43 <0.001' 1.63 <0.001' - - 1 NA
Mean menopausal age 151 degree 0.97 0.02' 0.98 0.24 0.90 0.007' 0.91 0.01' 0.91 0.01'
relatives
Environmental
Smoking (ever) 1.30a 0.048 ' 1.34 0.02' 1.35a 0.02' 1.44a 0.03' 1.46 0.03' 1.46 0.03'
BMI 0.98a 0.056 1.00a 0.87
Reproductive
Menarche 1.04a 0.41 1.05a 0.3054
Parity 0.85a 0.25 0.92a 0.5673
Hormone use (ever) 1.14a 0.34 0.99a 0.9272
Confounders
Age at interview 1.02 0.003' 1.02 0.01*
Ascertainment site 1.52 0.004' 1.92 <0.001' 1.77 <0.001' 1.93 <0.001' 1.99 <0.001' 1.99 <0.001'
HR: Hazard ratio; FMR1: Fragile X mental retardation 1; * significant at level a=0.05;
aall environmental and reproductive factors were adjusted for the FMR1 risk group at univariate analysis; Multivariate, only significantly associated factors are shown; Final 
model shows all variables selected for our model based on significant association for either premutation model or non-carrier model to improve comparability. HR >  1
indicate increased odds for an earlier menopause (risk factor), HR <  1 indicate a longer time to menopause (protective factor).
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Figure 3 Predicted survival curves for reaching postmenopausal state for 
high and low risk premutation women
age
Kaplan Meier estimates of probability of reaching postmenopausal state for high risk premutation 
women (with repeat size 80, smoking, mean menopausal age of first degree relatives 38 years and 
ascertainment location Nijmegen; dashed curve) and low risk, based on the non-carriers model 
(repeat size 50, never smoked, mean menopausal age of first degree relatives 55 and location 
Atlanta; solid curve) with 95% confidence bands
repeat sizes in Figure 4. On average, the fit of the premutation carrier and the 
non-carr ier model was good, as shown by inspecting the tertile plots (Figure 5). 
Only for sub jects in the terti les with the latest predicted menopause, the observed 
Kaplan Meier curves suggested a som ewhat later start of m enopause as predicted 
by the Cox model,  but this d i fference was only a few months. Internal validation of 
the premutation model showed that the op t im ism  in R2Nagelkerke, original value 0.09 
(95%CI: 0.04 - 0.15), was 0.01. The opt im ism in the concordance  index c, original 
value 0.66 (95%CI: 0.61 - 0.70), was 0.008. The linear shrinkage factor appeared 
to be 0.95. For the non-carr iers com parab le  values were seen: R2Nagelkerke =  0.09 
(95%CI: 0.06 - 0.18), op t im ism =  0.02; c =  0.69 (95%CI: 0.62 - 0.75), op t im ism = 
0.005 and shrinkage factor =  0.90.
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Figure 4 Predicted survival curves for reaching postmenopausal state by 
varying predictor combinations
age
Kaplan-Meier estimates of probability of being postmenopausal are provided for each 
ascertainment location varying repeat size and mean age of menopause for first degree relatives 
and fixing smoking. For the Atlanta location: repeat size 50, smoking, mean menopausal age of first 
degree non-carrier relatives (curve 1); repeat size 70, smoking, mean menopausal age of first 
degree relatives carrying a premutation (curve 2); repeat size 80, smoking, mean menopausal age 
of first degree relatives carrying a premutation (curve 3). For the Nijmegen location: repeat size 50, 
smoking, mean menopausal age of first degree non-carrier relatives (curve 4); repeat size 70, 
smoking, mean menopausal age of first degree relatives carrying a premutation (curve 5); repeat 
size 80, smoking, mean menopausal age of first degree relatives carrying a premutation (curve 6). 
The curves 1 and 4 are based on the non-carrier model and the curves 2, 3, 5 and 6 on the 
premutation model.
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Figure 5 Fit of our prediction models
age
Panel A shows Kaplan-Meier estimates of observed menopausal age and the predicted 
menopause by our model for non-carriers for tertiles based on observed menopausal age. Panel B 
shows Kaplan-Meier estimates of observed menopausal age and the predicted menopause by our 
model for premutation carriers for tertiles. Smoothed curves represent the observed data and 
stepped curves the predicted data.
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Discussion
By using a selected cohort of 1,068 women, we built a FXPOI prediction model 
based on FMR1 CGG repeat size, menopausal age of first degree relatives, and the 
environmental factor smoking, together with a correction for ascerta inment location. 
We found that this model can predict the risk for menopause at a certain age, as 
indicated by the acceptab le fit, the small confidence intervals and the good results 
of the internal validation procedure (i.e., small amounts of optim ism in R2 and 
concordance index c and a shrinkage factor close to 1). To our knowledge, this is 
the first model developed to help predict menopausal age in FMR1 premutation 
carriers. Other reproductive factors such as menarche and hormone use were not 
significantly associated with menopausal age in the premutation carriers, and thus 
not included in the prediction model. Van Noord et al. (12) reported that the impact 
of environmental factors on menopausal age is limited, which seems to be true for 
premutation carriers as well. A prominent association with smoking (hazard ratio of 
1.34) and menopausal age in premutation carriers was found, in accordance with 
data previously reported by Allen et al. (13) The toxic effect of smoking could give 
rise to destruction of the primordial oocytes at the level of the ovary (28) and could, 
therefore, accelerate the onset of FXPOI.
Many studies deal ing with relationship between various factors, such as menarche, 
OC use, BMI and parity, and early menopause (including POI and EM) have 
turned out to be controversial (12;29-32). In our set of premutation carriers no 
signif icant association with m enopausa l age was seen for these factors.
In the final mode l the FMR1 CGG repeat size, represented by ‘risk index by 
repeat size (RIR)’, is the m ost influentia l predictor. This was expec ted s ince the 
repeat size has been s trong ly  assoc ia ted with FXPOI before (13-16). To 
a cco m m od a te  the non- l inear assoc ia tion  of repeat size and risk for FXPOI and 
to avoid the som ew hat arb itrary c lass if icat ion of repeat groups, we used an 
HR -based app roach  and incorpora ted these risks relative to a reference repeat 
g roup into the pred ic t ion  model. In this  way the fast rise in risk after 60 CGG 
repeats and the s lower decline in risk after 100 CGG repeats can be modelled. 
The HR pattern for repeat size ind ica tes that a s ign if icant  high risk for FXPOI 
starts earlier and con t inues  longer than what was previously  reported (13;14). 
Due to the low HRs from 55-65 repeats, the higher risk at the end of the 
previously  de f ined 55-79 prem uta t ion  range m ight not have been evident before. 
The high risk around 105-110 repeats has never been desc r ibed  before and may 
be a t tr ibu ted to small num bers  (three w om en  with a repeat size of 110 and one 
with a repeat size of 105 and a m enopause  at a relatively young age). An isolated 
high risk for FXPOI based on a few repeats is cons idered  unlikely. Despite a 
small sam ple  size, a s ign if icant risk was also seen for 160 repeats. Thus, an
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elevated risk above 130 repeats cou ld  not be exc luded and requires further 
assessment.
D iscrepancies exist abou t risk for ovarian insuff ic iency am ong intermediate CGG 
repeat size carriers. Our analysis confirms that intermediate sized FMR1 CGG 
repeats should not be cons idered a high risk factor for ovarian insufficiency, as 
recently reported by Bennett et al. (33). In addition, we did not observe a higher 
risk for menopause at an early age am ong intermediate repeat alleles. We 
examined this association using the defined geno types  by Gle icher and his 
colleagues, where they defined a normal allele as those with 26-34 repeats and 
abnormal alleles as those outs ide of this range (34;35). None of the w om en in our 
study who were either heterozygous or hom ozygous abnormal had menopausal 
age before the age of 40. Most had m enopausa l age above 45 years. Addit ional 
stud ies need to be conducted  to further evaluate the association of these 
geno types  on phenotypes associa ted with ovarian function (36-39).
We observed a signif icant effect of ascerta inm ent location of our s tudy population. 
Several possib le explanations for this effect have been explored. We excluded a 
d i fference in d is tr ibution of CGG repeat sizes and the proport ion of premutation 
carriers in both groups  as a basis for the observed ascerta inm ent location effect. 
Also, a d ifference in genetic  background of the Dutch and American populations 
seems unlikely because of the inclusion of Caucasians only. Most Caucasian 
Am ericans are from European descent. One explanation cou ld be the manner in 
wh ich the interviews were taken. In the Atlanta study, the reproductive questionnaire 
was part of a large assessment, often including neuropsycho log ica l,  medica l and 
neurolog ica l assessments as well. The Nijmegen s tudy was set up for reproductive 
evaluation and the study in formation included a descrip t ion of FXPOI, which 
cou ld result in partic ipants report ing menopause at an earlier age than when it 
actually occurred.
A limitation of all cross-sectional s tudies is the use of t im e-dependen t variables 
such as smoking, BMI, parity, and hormone use. Such variables are preferably 
analyzed by an extended Cox proportional hazards model.  However, exact 
in formation of these variables per sub ject at different t ime points between 25 
years of age and the start of m enopause were lacking. Therefore, these variables 
were appl ied as if they were fixed at the age of 25 years. Even though this is a raw 
approximation of the reality, results based on this approach are at least indicative 
for the overall effect of these variables on m enopausa l age. In addition, age at 
m enopause is a transitory state and sub ject to report ing and recall bias. A 
previous study on recall of m enopausa l age showed a bias towards the mean as 
w om en deviated from the final menstrual period (40). In our case, recall and 
m em ory  bias m ight have led to an earlier menopausa l age because of awareness 
for FXPOI.
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Furthermore, we have used age at menopause as a surrogate for severity of 
FXPOI, but in general POI should not be cons idered a natural menopause, 
because of intermittent ovarian function and a 5-10% chance of pregnancy after 
d iagnosis (41). We used the definition of am enorrhea for at least 1 year due to 
menopause as a uniform criterion that appl ies to older and younger women. 
Taken together, our data strongly indicate that a prediction model for FXPOI is 
feasible, when tak ing ascerta inment site into account. This effect clearly confirms 
the im portance of data collection and ascerta inm ent protocols, as they could 
bias results. Nevertheless, we cons ider our model as a first step in developing 
clinically app l icab le  risk estimates for FXPOI, wh ich cou ld facil itate counseling. 
To further develop and individualize risk estimates for FXPOI, a predictor based 
on endocr ine markers, such as AMH, cou ld be included. AMH is an early marker 
of ovarian reserve and a very promis ing predictor for menopause and POI in 
general, and for premutation carriers in particular (42). The decline in ovarian 
reserve with t ime in premutation carriers with FXPOI, however, is not fully 
com prehended yet. Development of reference values of AMH by age for 
premutation carriers might al low early identi fication of w om en at high risk for 
FXPOI. In addition, examination of different ethnic/racial groups m ight be 
im portant in these prediction models. Studies have shown that the frequency 
distr ibution of FMR1 alleles differs am ong groups (43;44), however, no studies 
have examined whether the affect of the FMR1 alleles differs by ethnic/racial 
group. Using our current model based on RIR, mean m enopausa l age of first 
degree relatives with the same mutation status and smoking, premutation carriers 
with a high risk for FXPOI m ight benefit from monitor ing of ovarian reserve 
regularly and cons ider vitrif ication, i.e., c ryopreservat ion of oocytes.
Acknowledgements
We would like to thank the volunteers and their famil ies whose partic ipation made 
the work  possib le. This work was supported in part by National Institutes of Health 
grants NIH RO1 HD29909 and NIH PO1 HD35576 (SLS, EGA).
62
3#
Risk model development for FMR1 premutation carriers
References
(1) Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ. Heterozygous fragile X female: 
historical, physical, cognitive, and cytogenetic features. Am J Med Genet 1991; 38(2-3):269-274.
(2) Schwartz CE, Dean J, Howard-Peebles PN et al. Obstetrical and gynecological complications in fragile X 
carriers: a multicenter study. Am J Med Genet 1994; 51(4):400-402.
(3) Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D et al. Fragile X premutation is a significant risk factor for 
premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data. Am J Med 
Genet 1999; 83(4):322-325.
(4) Murray A, Webb J, Grimley S, Conway G, Jacobs P. Studies of FRAXA and FRAXE in women with premature 
ovarian failure. J Med Genet 1998; 35(8):637-640.
(5) Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol 
(Oxf) 2008; 68(4):499-509.
(6) Verkerk AJ, Pieretti M, Sutcliffe JS et al. Identification of a gene (FMR-1) containing a CGG repeat coincident 
with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65(5):905-914.
(7) Kronquist KE, Sherman SL, Spector EB. Clinical significance of tri-nucleotide repeats in Fragile X testing: a 
clarification of American College of Medical Genetics guidelines. Genet Med 2008; 10(11):845-847.
(8) te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002; 
8(2):141-154.
(9) Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertil Steril 1995; 
64(4):740-745.
(10) de Bruin JP, Bovenhuis H, van Noord PA et al. The role of genetic factors in age at natural menopause. Hum 
Reprod 2001; 16(9):2014-2018.
(11) Treloar SA, Do KA, Martin NG. Genetic influences on the age at menopause. Lancet 1998; 352(9134):1084- 
1085.
(12) van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde ER. Age at natural menopause in a population- 
based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril 1997; 68(1):95-102.
(13) Allen EG, Sullivan AK, Marcus M et al. Examination of reproductive aging milestones among women who carry 
the FMR1 premutation. Hum Reprod 2007; 22(8):2142-2152.
(14) Sullivan AK, Marcus M, Epstein MP et al. Association of FMR1 repeat size with ovarian dysfunction. Hum 
Reprod 2005; 20(2):402-412.
(15) Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in 
FMR1 premutation carriers. Eur J Hum Genet 2006; 14(2):253-255.
(16) Tejada MI, Garcia-Alegria E, Bilbao A et al. Analysis of the molecular parameters that could predict the risk of 
manifesting premature ovarian failure in female premutation carriers of fragile X syndrome. Menopause 2008; 
15(5):945-949.
(17) Nolin SL, Brown WT, Glicksman A et al. Expansion of the fragile X CGG repeat in females with premutation or 
intermediate alleles. Am J Hum Genet 2003; 72(2):454-464.
(18) Fu YH, Kuhl DP, Pizzuti A et al. Variation of the CGG repeat at the fragile X site results in genetic instability: 
resolution of the Sherman paradox. Cell 1991; 67(6):1047-1058.
(19) Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 
42(1):121 -130.
(20) Brown WT, Houck GE, Jr., Jeziorowska A et al. Rapid fragile X carrier screening and prenatal diagnosis using a 
nonradioactive PCR test. JAMA 1993; 270(13):1569-1575.
(21) Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979; 
74(368):829-836.
(22) Do KA, Treloar SA, Pandeya N et al. Predictive factors of age at menopause in a large Australian twin study. 
Hum Biol 1998; 70(6):1073-1091.
(23) Torgerson DJ, Avenell A, Russell IT, Reid DM. Factors associated with onset of menopause in women aged 
45-49. Maturitas 1994; 19(2):83-92.
63
#
#Chapter 3
(24) Hunter JE, Epstein MP, Tinker SW, Charen KH, Sherman SL. Fragile X-associated primary ovarian insufficiency: 
evidence for additional genetic contributions to severity. Genet Epidemiol 2008; 32(6):553-559.
(25) Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. 
Biometrika 1994; 81(3):515-526.
(26) Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika 1990; 
77(1):147-160.
(27) Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman and Hall, 1993.
(28) Neal MS, Zhu J, Foster WG. Quantification of benzo[a]pyrene and other PAHs in the serum and follicular fluid 
of smokers versus non-smokers. Reprod Toxicol 2008; 25(1):100-106.
(29) Progetto Menopausa Italia Study Group. Premature ovarian failure: frequency and risk factors among women 
attending a network of menopause clinics in Italy. BJOG 2003; 110(1):59-63.
(30) Cramer DW, Xu H, Harlow BL. Does „incessant" ovulation increase risk for early menopause? Am J Obstet 
Gynecol 1995; 172(2 Pt 1):568-573.
(31) de Vries E, den Tonkelaar I, van Noord PA, van der Schouw YT, te Velde ER, Peeters PH. Oral contraceptive use 
in relation to age at menopause in the DOM cohort. Hum Reprod 2001; 16(8):1657-1662.
(32) Stanford JL, Hartge P, Brinton LA, Hoover RN, Brookmeyer R. Factors influencing the age at natural menopause. 
J Chronic Dis 1987; 40(11):995-1002.
(33) Bennett CE, Conway GS, Macpherson JN, Jacobs PA, Murray A. Intermediate sized CGG repeats are not a 
common cause of idiopathic premature ovarian failure. Hum Reprod 2010; 25(5):1335-1338.
(34) Gleicher N, Weghofer A, Barad DH. Ovarian reserve determinations suggest new function of FMR1 (fragile X 
gene) in regulating ovarian ageing. Reprod Biomed Online 2010; 20(6):768-775.
(35) Gleicher N, Barad DH. The FMR1 gene as regulator of ovarian recruitment and ovarian reserve. Obstet Gynecol 
Surv 2010; 65(8):523-530.
(36) Bodega B, Bione S, Dalpra L et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in 
premature ovarian failure manifestation. Hum Reprod 2006; 21(4):952-957.
(37) Bretherick KL, Fluker MR, Robinson WP. FMR1 repeat sizes in the gray zone and high end of the normal range 
are associated with premature ovarian failure. Hum Genet 2005; 117(4):376-382.
(38) Gleicher N, Weghofer A, Barad DH. A pilot study of premature ovarian senescence: I. Correlation of triple CGG 
repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Mullerian hormone. Fertil Steril 2009; 
91(5):1700-1706.
(39) Gleicher N, Weghofer A, Oktay K, Barad D. Relevance of triple CGG repeats in the FMR1 gene to ovarian 
reserve. Reprod Biomed Online 2009; 19(3):385-390.
(40) Rockhill B, Colditz GA, Rosner B. Bias in breast cancer analyses due to error in age at menopause. Am J 
Epidemiol 2000; 151(4):404-408.
(41) Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early 
menopause. Fertil Steril 2005; 83(5):1327-1332.
(42) Rohr J, Allen EG, Charen K et al. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental 
retardation (FMR1) premutation carriers: a preliminary study. Hum Reprod 2008; 23(5):1220-1225.
(43) Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. 
Genet Med 2001; 3(5):359-371.
(44) Gleicher N, Weghofer A, Barad DH. Effects of race/ethnicity on triple CGG counts in the FMR1 gene in infertile 
women and egg donors. Reprod Biomed Online 2010; 20(4):485-491.
64
#Risk model development for FMR1 premutation carriers
Supplement heritability of menopausal age
Material and methods
Heritabil i ty  was determ ined by a m axim um  likelihood approach as imp lemented in 
the ASSOC program of the Statistical Analysis in Genetic  Ep idem io logy (S.A.G.E.) 
package, version 6.1 .[1] ASSOC uses a linear regression model, in wh ich the 
residual variance is parti t ioned into the sum of an addit ive po lygenic com ponent 
and a sub ject-spec if ic  random com ponent.  Heritabil i ty  is expressed as the 
po lygenic variance div ided by the total residual variance.
Results
The large fam ily-based dataset presented here allowed a determination of 
heritabil i ty of m enopausa l age for fragile X famil ies. Since the software program 
S.A.G.E. is unable to differentiate censored data from well-defined menopause, 
heritabil i ty could only be determ ined for wom en with a well-defined age at 
menopause. The overall heritabil i ty of age at menopause for premutation carriers 
and non-carr iers was 0.72. After correcting for the premutation (as d icho tom ous 
variable), a heritabil i ty of 0.43 was left. Further assessments  were performed on 
premutation carriers and non-carr iers separate ly (Table 1). The total residual 
variance of m enopausa l age was large am ong premutation carriers with a low 
heritabil i ty of m enopausa l age am ong premutation carriers, i.e., 0.22. N on­
carriers exhib ited a smaller total residual variance in m enopausa l age, with a 
large po lygenic com ponen t  and a heritabil i ty of 0.71 (Table 1).
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Table 1 Heritabili ty and variances of menopausal age for different models including polygenic effect
Prem utation N= 197 Non-carriers 
N = 193
Models Total variance Polygenic
variance
Heritability Total variance Polygenic
variance
Heritability
No parameter adjustment 44.61 9.87 0.22 22.43 16.33 0.73
Genetic
Risk index by repeat 44.11 8.33 0.19 NA
Environm ental
Smoking 43.98a 8.39a 0.19a 22.01 17.54 0.80
BMI 43.99a 7.67a 0.18a 22.40 15.74 0.70
Reproductive
Parity 39.51 a 7.24a 0.18a 21.77 14.81 0.68
OC 43.95a 7.76a 0.18a 22.34 16.33 0,73
Menarche 44.04a 9.8a 0.22a 22.33 16.67 0,75
Multivariate 39.08 b 7.24tl 0.19 b 21,49 e 15.76° 0.73 G
a: Corrected for risk index by repeat for premutation carriers; b: corrected for risk index by repeat, smoking, BMI, parity, OC-use and menarche; c: corrected for 
smoking, BMI, parity, OC-use and menarche.
#Risk model development for FMR1 premutation carriers
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Intra-individual stability over time of 
standardized anti-Mullerian hormone in 
FMR1 premutation carriers
#Chapter 4
Abstract
Background: Carriers of a premutation (CGG repeat length 55-200) in the fragile 
X mental retardation (FMR1) gene are at risk for pr imary ovarian insuffic iency 
(FXPOI). The anti-Mullerian horm one (AMH) level acts as a useful marker of 
ovarian foll icle reserve and, thus, may serve to predict when this ovarian reserve 
becom es too low to sustain ovarian function. We investigated the in tra-individual 
variation of AMH levels over t ime for premutation carriers com pared  with 
non-carriers.
M ethods: We determ ined AMH levels in b lood sam ples from 240 wom en 
ascerta ined th rough fragi le X famil ies, of wh ich 127 were premutation carriers and 
113 non-carriers. Linear mixed m odels  were used to assess the effect of age and 
premutation status on AMH levels and to determine a m odeled AMH value. The 
stabil ity over t ime of the devia tion of observed AMH levels from m odeled levels, 
referred to as standard ized AMH values, were assessed th rough correlation 
coeffic ients of 41 longitudinal samples.
Results: At all ages premutation carriers exhib ited lower AMH levels. For all 
women, AMH was found to decrease by 10% per year. The added effect of having 
a premutation decreased AMH levels by 54%. The deviation of an ind iv idual’s 
AMH level from the m odeled value showed a reasonable in tra-individual 
correlation. The Pearson corre lat ion coeffic ient of two samples taken at different 
ages was 0.36 (p=0.05) for non-carr iers and 0.69 (p =  0.01) for carriers. 
Conclusion: We developed a unique standard ized AMH value, tak ing FMR1 
premutation status and the sub je c t ’s age into account, wh ich appears  to be 
stable over t ime and may serve as a predictor for FXPOI after further longitudinal 
assessment.
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Introduction
Age related female fecund ity  depends  on the reserve of the ovarian foll icle pool 
(ovarian reserve) and the qual ity of the germ cells with in this pool. With increasing 
age female fecundity  declines and ferti li ty deteriorates until m enopause occurs, 
a round the age of 51 years (1;2). Some w om en already have a d im inished ovarian 
reserve at a relatively young age, wh ich is referred to as ovarian insuff iciency. 
The spectrum  of ovarian insuff ic iency ranges from d im inished ovarian reserve to 
pr imary ovarian insuff ic iency (POI), previously referred to as premature ovarian 
fai lure (POF), wh ich is defined as am enorrhea for at least 4 months and post­
m enopausa l FSH levels before the age of 40 years.
In the past years, various markers, such as foll icle stimulating horm one (FSH) 
serum levels or antral foll icle count, have been used to measure ovarian 
insufficiency, but most of these markers only indicate advanced ovarian 
senescence. More recently, it was reported that the anti-Mullerian hormone (AMH) 
level may act as a useful marker for the ovarian foll icle pool (3). Therefore, AMH 
levels may serve as a marker for the ovarian foll icle reserve during its natural 
decline (i.e., ovarian senescence) and, hence, for the risk of a low ovarian reserve 
at a young age (i.e., early ovarian senescence) and early exhaustion of the follicle 
pool (POI), wh ich thereby can be identi fied earlier.
It has been we ll-docum ented that female carr iers of a premutation in the fragile X 
mental retardation (FMR1) gene have an increased risk of early ovarian failure 
(4-7), referred to as fragi le X-associated primary ovarian insuff ic iency (FXPOI) (8). 
The premutation represents an expansion of a tr inucleot ide (CGG) repeat in the 5 ’ 
untranslated region of the FMR1 gene (9). The premutation (55-200 CGG repeats) 
can further expand to a full mutation with at least 200 CGG repeats, causing 
fragile X syndrom e (MIM 309550), the most com m o n heritable cause of intel lectual 
and developmenta l disabili ties. A normal allele with <45  CGG repeats is stably 
inherited, but an intermediate allele (45 to 54 CGG repeats) may show instabil ity 
upon t ransm iss ion (10). Within the premutation range a high risk for FXPOI has 
been suggested for —80-100 repeats (7;11-13). W omen with a normal repeat 
length or a full mutation are not at risk for POI (4;14). Recent s tudies suggest that 
repeat sizes between 35 and 55 may cause early ovarian senescence (15-17); 
however, Bennett et al. (18) failed to observe a s ignif icantly  increased frequency 
of in termediate size repeat alleles am ong a large group of w om en with POI. 
Recently, Rohr et al. (19) measured AMH serum levels in premutation carriers in 
their c ross-sectional s tudy and found indications of reduced ovarian reserve even 
at early ages (18-30). AMH levels may serve as promis ing predictors of menopausal 
age, as is illustrated by a num ber of s tudies (20-22). A recent s tudy reported the 
deve lopm ent of a model to predict m enopause based on AMH levels with
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consis tent agreement between predicted and actual ages at m enopause among 
naturally fertile w om en (23). As a coro llary of the w ork  reported by Rohr et al. (19), 
and the high predictive value of AMH levels for m enopause in the general 
population, we hypothesized that the decline in AMH is stable in carriers and 
non-carriers. If ev idence supports  this hypothesis, AMH may be used in the future 
to assess the ovarian reserve prior to early ovarian senescence. To test this 
hypothesis, we investigated the intra-indiv idual longitudinal variation of AMH 
levels am ong premutation carriers and non-carr ier w om en of fragi le X families, 
ad justing for the premutation status and age.
Materials and methods
Subjects
The study sam ple com prised part ic ipants from two centers, the Radboud 
University Ni jmegen Medical Centre, Ni jmegen, the Netherlands and the Emory 
University, Atlanta, GA, USA. After being informed about the objective and design 
of the present study, all part ic ipants provided informed consent. The study was 
approved by the institutional review boards (number NL23358.091.08; USA 
100-2000). {g }
The N ijm egen study
All fragi le X famil ies that were d iagnosed at the Departm ent of Human Genetics 
Ni jmegen between 1984 and 1998 were ascerta ined for this study. All female 
relatives of the proband aged 18 to 55 years were approached to partic ipate in 
the present study, to com ple te  a general health and reproductive history 
questionnaire and to supp ly  a serum sample, as descr ibed in detail by Hundscheid 
et al. (24). Briefly, part ic ipants with a natural menstrual cycle provided blood 
samples on the third day of their cycle (early fo ll icular phase). For w om en using 
hormones, in all cases oral contraceptives (OC), blood samples were obtained on 
the last day of the (7-day) pill-free interval. B lood sam ples taken on day 3 of the 
menstrual cycle or on the last day of a hormone-free interval have been reported 
to show FSH levels com parab le  to those in the early fo ll icular phase (25;26).
The Atlanta study
The Atlanta cohort  from the Departm ent of Human Genetics included w om en who 
were recruited th rough the Emory Study of Adult Learning and Reproduction.
Ascerta inm ent protocols have been descr ibed in detail by Sullivan et al. (7) and 
Rohr et al. (19). Briefly, to ascerta in a large sam ple of varying repeat size (both 
intermediate and premutation alleles) both famil ies with fragi le X syndrom e and
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women in the general population were surveyed. For both ascertainment strategies, 
females aged 18-75 were asked to com ple te  a reproductive history questionnaire 
and to provide a buccal or blood sam ple for FMR1 CGG repeat size determination. 
In addition, for w om en who were still cycling or on hormone medication, blood 
sam ples were obta ined on the third day of their  cycle or of their pill-free interval, 
for the majority of samples. The most recent sam ples (N =  60) were col lected on 
any day of the menstrual cycle. For some sam ples in formation on hormone use 
was unavailable and therefore the model could not be adjusted for hormone use.
The fo llowing inclusion criteria were appl ied for partic ipation in this study: 1) aged 
18-55 years; 2) FMR1 mutation status determined; and 3) menstruating at least 
once every three months or using horm ones or oral contraceptives. After inclusion 
and AMH m easurement a fourth criterion was applied, namely, undetectable AMH 
levels were excluded from analyses because they cannot be corrected for age 
and mutation status. Moreover, for this particular appl icat ion to assess the stabili ty 
of the standard ized AMH, undetectable AMH levels cannot be used because they 
are unable to further decline over time. W omen with ia trogenic  menopause (after 
bilateral ovariectomy, radiation therapy or chemotherapy), ovarian surgery or 
po lycystic ovary syndrom e (PCOS) as defined by Rotterdam 2003 criteria (27) at 
any point in t ime were excluded from the study. The detailed study design is 
shown in Figure 1.
Data collection
D elineation o f serum samples co llec ted  fo r both cohorts
For the Nijmegen cohort, stored serum samples col lected in 1998 and 1999 (24) 
were used. Suffic ient am ounts  of frozen serum were available for AMH assays of 
108 w om en from 50 unrelated fragi le X families.
For the Atlanta cohort  stored serum samples were col lected between 2002 and 
2009 for FSH and AMH studies. Suffic ient am ounts  of frozen serum were available 
for AMH assay of 219 w om en from 157 famil ies. For a subset (115) of these 
women, AMH levels were determ ined and reported before (19). In total 307 wom en 
from 180 famil ies met the inclusion criteria and partic ipated in this study, 108 
sam ples from the Nijmegen cohort  and 219 from the Atlanta cohort .
From all AMH values determined, 67 had an undetectable AMH level and were 
excluded from our study. Analyses were done on the 240 w om en with measurable 
AMH levels, of wh ich 127 were premutation carr iers and 113 non-carriers. For 41 
of these 240 women, 12 premutation carriers and 29 non-carriers, a second 
serum sam ple was taken under the same cond it ions and resulted in AMH levels 
above detection limit. The t ime interval between the 2 sam ples varied from 1.5 
year to 10 years.
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Figure 1 Flowchart of the study sam ple by location
Nijmegen
Atlanta Atlanta
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H orm one assays
Serum derived from blood sam ples was stored at -35°C until use for the Nijmegen 
cohort. AMH levels were measured using an Enzyme-Linked Immunosorbent 
Assay (ELISA, D iagnost ic  System Laboratories, Inc./Beckman-Coulter). The 
detection limit of this assay is 0.10 ng/ml. Intra- and inter-assay coeffic ients of 
variation were <5%  and <8%, respectively (28).
For the Atlanta subset serum sam ples were stored at -70°F until use. AMH levels 
were measured with the same Beckm an-C oulte r kit, with a detection limit of 0.05 
ng/ml and a similar intra- and inter-assay coeffic ient of variation.
FMR1 CG G  repeat size m easurem ent
From partic ipants inc luded in the Dutch study, DNA was extracted from peripheral 
b lood cells. PCR amplif ication of the FMR1 alleles was performed using fluorescein 
(FAM)-labeled reverse primers as descr ibed by Fu et al. (29). PCR cond it ions are 
available upon request. Fragment lengths were measured using an ABI prism 
3730 DNA Analyser (Applied Biosystems) and quantif ied using ABI prism 
G enem appe r Analysis Software v4.0 (Applied Biosystems).
From w om en part ic ipat ing th rough Atlanta, DNA was extracted from buccal 
sam ples or peripheral b lood cel ls using Qiagen Q iAm p DNA Blood Mini Kit. FMR1 
CGG repeat sizes were determ ined by a f luo rescent-sequencer method as 
descr ibed elsewhere (30), using an ABI Prism 377 DNA Sequencer or the ABI 
3100 Genetic  Analyzer. For females showing only one FMR1 allele upon 
sequencing, a second PCR-based, hybrid ization techn ique was used to detect a 
possib le larger fragment. The protocol used for this is a modif ied version of that 
developed by Brown et al. (31). If no high repeat allele was detected using this 
fo l low-up strategy, we conc luded  that the w om an in question was hom ozygous 
for the smaller allele.
Statistics
AMH serum levels exhibit a posit ively skewed distr ibution due to the age-related 
decline that falls be low the detection limit. Natural logarithmic (log) trans fo rm a­
t ions of AMH serum levels were appl ied to transform these distr ibutions to 
normality. A linear mixed model was used to assess the effect of age and 
premutation status on AMH levels and to calcula te a m odeled AMH value based 
on age (continuous variable, years) and premutation status (d ichotomous variable: 
non-carr ier=0, premutation carrier=1). This model included a random family 
intercept to account for possib le with in-family correlation. If AMH was measured 
at different occas ions  for a subject, only the first observation was used to develop 
this model.
75
#
#Chapter 4
For every individual, the m odeled logarithmic transformed AMH value was defined 
by the regression equation: y 1=log(AMH) =  in tercept+a*age +  p*premutation: 
where a  and (3 represent the estimated effects of age and premutation, respectively. 
The deviation of an ind iv idual’s observed log(AMH) level from the m odeled y 1 
value is defined as:
Standardized AMH =  [Observed log(AMH) - Modeled log(AMH)] /  residual standard 
deviation, where the residual standard deviation results from fit ting the linear 
model to the first observed AMH values. For subjects with two AMH values 
observed at different ages, we determ ined the second standard ized AMH value 
using the coeffic ients from the regression equation fitted on the first observations 
as descr ibed above, but now using the observed AMH level taken at the second 
t ime point. The Pearson correlation coeffic ient between the first and second 
s tandard ized AMH values and scatterp lots  were used to examine the stabil ity of 
the s tandard ized AMH values over t ime with in subjects.
Apart  from the assessm ent of stabil ity of s tandard ized AMH, the di fference in 
AMH levels between premutation carriers and non-carr iers was determined. In 
order to com pare AMH levels from premutation carriers and non-carriers, we 
m odeled the best fitting curves for both groups on the full set of AMH levels, 
including first and second AMH samples. The best fit ting curves were constructed 
by a multi level mixed linear model, accounting  for the clustering of observations 
within a sub ject and clustering of subjects with in a family. All m odels were based 
on the logarithmic transformed AMH values using age and premutation status as 
independent variables.
Analyses using linear mixed models were carried out with Statistical Analysis Software 
(SAS), version 8.2. Statistical significance was considered to be present at p  <0.05.
Results
Analyses were performed on the total dataset of 240 w om en with detectable AMH 
serum levels. The median age at wh ich the b lood sam ples were taken was 37 
(range 18-55) years for premutation carriers and 31 (range 20-51) years for 
non-carriers. The median ages and repeat sizes per location are provided in 
Table 1. The dis tr ibution of AMH serum levels by age for both premutation carriers 
and non-carr iers conf irmed the previously descr ibed (19) lower ovarian reserve 
for premutation carriers at all ages (Figure 2).
D evelopm ent of m odeled AM H values
In order to correct AMH serum levels for effects of the premutation and age on the 
ovarian reserve, a m odeled AMH value was developed using linear mixed model
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Table 1 The median ages and repeat sizes by location
Number of Median age Median repeat
patients (years) length*
[p25-p75] [p25-p75]
Carriers Nijmegen 32 37 [34-41] 89 [82-99]
Carriers Atlanta 95 34 [30-41] 90 [79-100]
Non-carriers Nijmegen 37 36 [31-40] 31 [29-39]
Non-carriers Atlanta 76 28 [23-39] 41 [30-44]
* The median repeat length of the largest allele.
analyses. By do ing so, we found a statis tically s ignif icant effect on our ou tcom e 
measure, observed log(AMH), of -0.11 for each year a person aged (p<0.0001) 
and -0.78 for premutation carrier status (p<0.0001). Our model y ie lded the 
fo llowing equation to determine the m odeled AMH value:
M odeled log(AMH) =  3.81 - 0.11*age - 0.78*premutation.
The random intercept al lowing with in family corre lat ion was 0, the residual 
standard deviation was 1.133. These m odeled log(AMH) values were transformed 
back  to the original scale for interpretation to describe whether the observed 
AMH values were above or be low the m odeled AMH values, imply ing a larger or 
lower ovarian reserve as expected for an ind iv idua l ’s age and premutation 
status.
Deviation from  m odeled AM H: standardized  AM H is stable over time
The interpretation of an indiv idual AMH level was quantif ied by the devia tion of the 
observed measured log(AMH) level from the m odeled log(AMH) values divided 
by the residual s tandard deviation, wh ich is term ed ’s tandard ized AMH va lue ’. 
The standard ized AMH values ranged from -2.9 to 2.7 for premutation carr iers 
and from -3.6 to 1.9 for non-carriers. W omen with an additional second sample 
were used to assess the stabil ity of the decline in AMH levels over time. The 
correlation coefficients of the standardized AMH values derived from the two time 
poin ts was reasonable, with a Pearson corre lat ion coeffic ient of 0.36 with 95%CI: 
-0.005 - 0.64, (p =  0.05, n=29) for non-carr iers and 0.69 with 95%CI: 0.19 - 0.91, 
(p = 0 .0 1 , n=12) for premutation carriers (Figure 3). This reasonable con form ity  is 
indicative of a small intra-indiv idual variation in s tandard ized AMH values and 
stabil ity over t ime, both attr ibutes being beneficial to a possib le predictor for 
m enopause in premutation carriers.
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Figure 2 Scatterplot of AMH levels by age for premutation carriers and 
non-carriers
Age (years)
Closed circles depict premution carriers and open circles depict non-carriers. The best fitting 
curves (solid line for premutation carriers and dashed line for non-carriers) were constructed by a 
multilevel mixed linear model, accounting for the clustering of observations within subjects and 
clustering of subjects within families, on the logarithmic transformed AMH values. For this model 
we used as independent variables age and premutation status.
A ge-re lated  decline in AMH
The age-re lated decline in AMH, and the di fference in decline between premutation 
carriers and non-carr iers was assessed using a multi level mixed linear model 
(see Methods). On the logarithmic scale this model indicates a premutation effect 
of -0.76 (p <  0.0001), wh ich means that at each age the value of AMH in a 
premutation carrier is on average 46% (exp(-0.78)) of that in a non-carr ier of the 
same age. For both carriers and non-carriers, the effect of aging is a decrease of 
10% (exp(-0.11)) in AMH levels per year, starting at the age of 18 years. Figure 2 
shows the results on the original AMH scale.
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Figure 3 Correlation of standardized AMH values
First Standardized AMH
Correlation of standardized AMH values in subset of premutation carriers (closed circle; R=0.69, 
p=0.01) and non-carriers (open circle; R=0.36, p=0.05) with two AMH measurements at different 
ages as shown on a linear regression curve (solid line for premutation carriers and dashed line for 
non-carriers).
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Discussion
This is the first s tudy to assess age and prem utat ion-corrected AMH serum levels 
in premutation carriers w ho are at risk for FXPOI. Using these data, we propose a 
s tandard ized AMH which is stable over t ime in premutation carriers and 
non-carriers. Several steps were taken to develop this standard ized variable. 
First, a large dataset was derived by pool ing sam ples from two  cl inical centers 
addressing FMR1 premutation carriers and their reproduction. The col laboration 
also resulted in a more representative sam ple with regard to age and repeat size 
ranges. Second, a model was developed to determine an ind iv idua l ’s modeled 
AMH based on age and premutation status by linear mixed model analysis. 
Overall, we found that both age at AMH m easurement and premutation carrier 
status played a large role in m odeled AMH levels. Using the standard ized AMH 
levels, we found that the corre lat ion obtained at two t ime poin ts was higher for 
premutation carriers com pared  with non-carriers. We th ink that this can be 
expla ined by three non-carr ier w om en exhib it ing a s tandard ized AMH above their 
m odeled value at first sample and far be low their m odeled AMH value at second 
sample (Figure 3). Possible d ifferences in hormonal status, like pregnancy or OC 
use may play a role and should be cons idered when AMH levels are measured. 
To date, age-re lated decline in AMH serum levels has been studied for the general 
population and some sub-fert ile popu lat ions in relation to in vitro fertil ization (IVF) 
(32). AMH serum levels as a function of age have shown w ide variation, as 
depicted by Tremellen et al. (33). In their study on prediction of menopause, Van 
D isseldorp et al. (22) m odeled mean decline of AMH with age and appl ied a 
menopausa l threshold AMH level to corre late this predictive d is tr ibution with the 
distr ibution of observed age at menopause. There was a good  level of conform ity  
between the two  distr ibutions. A lthough their m odeled AMH level was based on a 
cross-sectional survey, the results are highly suggestive of AMH being a good 
predictor for menopausa l age.
Few studies addressed AMH decline by a longitudinal setup. De Vet et al. (34) 
showed a signif icant decrease over t ime of an indiv idual’s AMH level and a high 
correlation with age. Van Rooij et al. (35) expanded AMH as a marker for ovarian 
reserve a step further and assessed the consis tency of AMH over t ime in a 
comparable manner as this study. They investigated whether a w o m a n ’s individual 
level above or below the mean of her age group at time point 1 remained above or 
below the mean of her age group at t ime point 2. Serum AMH levels showed the 
best consis tency com pared to other ovarian reserve markers. Our current study 
took another step by correcting for age and assessing whether the consistency 
seen in normo-ovulatory wom en is also seen in premutation carriers, adjusting for 
the fact that carriers are known to be at risk for a lower ovarian reserve.
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Although there is evidence that AMH may serve as a potential FXPOI predictor, we 
have taken into account that the results are based on a relatively small longitudinal 
sample size, in spite of pooling samples from two clinical centres. There are several 
other directions that should be taken in future studies that we were not able to 
accommodate in this study. First, in our linear mixed model analyses the dichotomized 
variable of premutation status was used to adjust for the risk of FXPOI. However, we 
know that there is a non-linear association of risk for FXPOI and the size of the 
premutation, but we were unable to incorporate this effect due to our small sample 
size. We think that taking into account the non-l inear risk will provide better adjustments 
for the risk of low ovarian reserve for premutation carriers and, therefore, should be 
investigated further. Not only the size of premutation alleles, but also the intermediate 
repeat sizes could be involved in ovarian function and cause early ovarian senescence 
or premature ovarian aging as was recently shown (15-17;36). Comparison of AMH 
levels in our women with an intermediate repeat sizes (35-45 or 46-55 repeats; N=49) 
with AMH levels of repeat sizes <35, does not show lower AMH levels among women 
with intermediate CGG repeats (18-30 years, p=0.25; 31-40 years, p=0.67; >40 
years, p=0.48, Kruskal-Wallis test).
Second, we did not correct for use of horm ones or the phase of the menstrual 
cycle at the t ime the b lood sample was taken. Instead, we assessed the age- 
distribution of samples taken during OC use and found a similar normal distribution 
for premutation carriers and non-carriers, implying that an effect of OC use on the 
m odeled AMH values is unlikely. Furthermore sam ples taken at any t ime in the 
menstrual cycle were also normally distr ibuted by age for premutation carr iers 
and non-carriers. At first AMH levels were cons idered independent of hormonal 
variat ions (37-39). More recently, however, several s tudies have quest ioned this 
independency. Van den Berg et al. (40) showed a s ignif icant d i fference in both 
AMH and FSH levels in a natural cycle and the subsequent first and second 
hormone-free intervals. Also, circulat ing AMH levels have been shown to decline 
during the second and third tr imester of p regnancy (41).
The lower AMH levels among premutation carriers seen at all ages also emphasize 
the need for ways to enhance early identification of low ovarian reserve to facilitate 
counsell ing for FXPOI and concom itan t  family planning. M cConkie-Rossell et al. 
(42) have suggested that monitoring of ovarian function should be recommended 
when counsell ing premutation women, even though an exact delineation of the 
onset of FXPOI is difficult. Early identi fication of premutation carriers who will 
develop FXPOI is expected to lead to better chances of pregnancy, either 
spontaneous or by IVF. When pregnancy canno t be established due to lack of a 
partner or is pos tponed for other reasons, cryopreservat ion of oocytes by 
vi trif ication has recently been presented as a realistic option for ferti li ty preservation 
for young premutation carriers.
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In conclusion, we have developed an attractive method, using standard ized AMH 
values, wh ich may be suitable as a potential predictor for m enopausa l age in 
FMR1 premutation carriers at risk for FXPOI. Further assessm ent of our 
s tandard ized AMH value by a large longitudinal sam ple and association with 
menopausa l age will need to demonstra te its benefit as a predictor for FXPOI.
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Abstract
Background: Female carriers of a premutation in the FMR1 gene have an 
approximately  20% chance of develop ing fragile X-associated primary ovarian 
insuff ic iency (FXPOI), wh ich is a condit ion characterized by cessation of normal 
ovarian function before the age of 40 and FSH levels above 40IU/l. Here, we 
performed a genom e-w ide  linkage analysis in a family with excessive FXPOI to 
identi fy a putative modif ier locus affecting FMR1 premutation carriers.
M ethods: A g enom e-w ide  linkage scan was perfo rm ed in a family with 8 affected 
sisters using an Affymetrix GeneChip 250K (Nsp I) single nucleotide polymorphism 
(SNP) m icroarray platform. Linkage determ ination was perfo rm ed using an 
EasyLinkagePlus software package. The SNP data were independently confirmed 
using po lym orph ic  microsatell ite markers.
Results: Linkage analysis revealed a locus on chrom osom e 15q25 of 7.54 Mb in 
size (79.61 Mb-87.15 Mb) exhib it ing a m axim um  LOD score of 2.387 for PXPOI. 
A preliminary sequencing effort of two candidate genes, PDE8A (associated with 
fol l iculogenesis) and CYP19A1 (involved in the steroidogenesis), did so far not 
reveal any overt causative mutations.
Conclusion: G enom e-w ide linkage analysis in a family with excessive FXPOI 
revealed a candidate locus on chrom osom e 15q25, wh ich might be associa ted 
with susceptib i l i ty  to FXPOI in FMR1 premutation carriers. Mutations in this locus 
that are related to the d isorder still await their identification.
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Introduction
In the general population, m enopausa l age varies between 40 and 60 years. 
Approx im ate ly  1% of the population has its final menstrual period before the age 
of 40 years, wh ich has been denoted as premature ovarian failure (POF), and is 
defined by foll icle st imulating hormone (FSH) serum levels above 40 IU/l and 
am enorrhea for at least 4 months. Studies am ong POF w om en indicate that 
12.5-31% of these w om an have at least one affected family m em ber (1-3). Of all 
famil ial POF cases, 12% may be due to a premutation in the fragile X mental 
retardation 1 (FMR1) gene (4-6). In order to better illustrate the cont inuum of 
altered ovarian function and intermittently  returning ovarian function observed in 
w om en with POF, the preferred term has been altered in premature ovarian 
insuff ic iency (POI) (7), especia l ly in the context of the FMR1 premutation: fragile 
X-associated premature ovarian insuff ic iency (FXPOI) (8).
The (pre)mutation in the FMR1 gene represents an expansion of a tr inucleotide 
(CGG) repeat in its 5 ’ untranslated region (9). Based on the num ber of repeats 
present, four distinct of FMR1 alleles can be dis tinguished: 1) a normal allele with 
50 repeats, wh ich is stably inherited; 2) an intermediate allele with 45 to 54 
repeats, wh ich may show instabili ty upon maternal and paternal transmission; 3) 
a premutation allele with 55 to 200 repeats, wh ich can expand to 4) a full-mutation 
allele with at least 200 repeats, exclusively evolving from the premutated state 
when transm itted th rough a female germline (ACMG practice gu idelines (10)). 
Expansion beyond 200 CGG repeats causes hypermethylat ion and s ilencing of 
the FMR1 gene, wh ich encodes  the fragile X mental retardation protein (FMRP). 
Loss of FMRP expression results in the fragile X syndrom e (11;12).
Approximately 20% of the premutation carriers develops POI. However, excessive 
famil ia l c luster ing of FXPOI has occas iona l ly  been observed, whereas in other 
famil ies none of the prem uta t ion  carr iers exper ienced FXPOI and /o r  early 
m enopause (13;14).
In our assessm ent of reproduct ion am ong FMR1 premutation carriers we also 
noted a familial clustering of FXPOI in some of the cases examined. We hypothesize 
that genetic factors, other than FMR1 repeat length alone, may act as modif iers 
for FXPOI evolvement. In order to identi fy such a modifier(s) we preformed a 
genom e-w ide  linkage analysis in a large FMR1 premutation posit ive family 
excessively affected by FXPOI.
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Material and methods
Subjects
A Dutch family with 10 sisters carry ing a FMR1 premutation was ascerta ined 
because of excessive clustering of FXPOI (8 out of 10 sisters affected; Figure 1). 
After informed consent was given, the medica l history on general health and 
reproduct ion was taken by one physic ian (MS). To support  the self reported age 
at amenorrhea, medical records were retrieved whenever available. No endocrine 
confirmation of menopause was available from those records. Blood sam ples for 
DNA isolation were col lected after obtain ing written in formed consent. All sisters 
were ob ligate carriers because of paternal inheritance of the FMR1 premutation 
allele.
FMR1 analysis
G enom ic  DNA was isolated from peripheral blood using a Chem ag ic  Magnetic 
Separation Module 1 (Chemagen, Baesweiler, Germany) accord ing  to the 
manufacturer’s instructions. PCR amplif ication of the FMR1 alleles was performed 
using 6-carboxyfluorescein (FAM)-labeled reverse primers as descr ibed by Fu et 
al. (15). Fragment lengths were measured using an ABI prism 3730 DNA Analyser 
(Applied Biosystems, Nieuwekerk a/d IJssel, The Netherlands) and quanti fied 
using the ABI Prism G enem appe r Analysis Software v4.0 package (Applied 
Biosystems) with an accuracy of 1-2 repeats.
Genome-wide SNP scanning
The genom e-w ide  search was conducted  using DNA from 10 m em bers of the 
family, including 8 FXPOI patients. Affymetr ix  GeneChip 250K (Nsp I) arrays 
contain ing approximately  262,000 SNPs were used. Samples were processed 
accord ing  to the m anufacture r ’s instructions (Affymetrix Inc, Santa Clara, 
California, USA). The GeneChip G enotyp ing Analysis Software (Genotyping 
module) was used for geno type cal ling, quality contro l and the export of data.
Linkage analysis and locus identification
The statistical package EasyLinkage Plus v5.08 (16), designed to perform 
automated linkage analyses using la rge-scale SNP data, was used to perform 
linkage analyses. Since closely  spaced SNP markers can cause prob lem s related 
to linkage disequil ibrium, the analyses were performed after pruning using an R2 
of 0.05 in PLINK v1 .07 (17). All SNPs showing inconsistency in t ransm iss ion were 
removed from further analyses. GeneHunter v2.1r5 software (incorporated in the 
EasyLinkage Plus v5.08 package) was used to perform fully automated parametric 
multipoint linkage analyses. LOD scores were retrieved using a dom inant model
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Figure 1 Summarized genealogical tree of the FMR1 premutation family. Dotted symbols indicate FMR1 premutation carriers 
and solid black symbols
©  premutation 
©  normal repeat
N symbols indicate a normal CGG repeat size.
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of inheritance, with a penetrance of 8%, a phenocopy  rate of 0.01 and a disease 
allele f requency of 1:1000. The A ffymetr ix  500k Marshfield (NCBI 36.1, April 6, 
2007) m ap was used for the EasyLinkage analyses.
Hap lo types were constructed for single ch rom osom es showing posit ive linkage. 
Graphical visualization of haplo types to facil itate inspection and analysis was 
obta ined using the HaploPainter v029.5 software (18).
Microsatellite marker analysis
Microsatell ite markers were selected from the Human G enom e Browser Gateway 
(19)) Human Feb. 2009 (GRCh37/hg19) A ssem b ly  (track STS markers), based on 
location in regions of high LOD scores observed in the linkage analysis (conversion 
of Affymetr ix  SNP ID to Reference Cluster ID by bdSNP home page) and 
heterozygosity rates in the Caucasian population. Marker analysis using 
fluorescently labeled primers was performed according to the protocol for Linkage 
M apping Set MD10 version 2.5 (Applied Biosystems). Reactions for each marker 
were performed separately, with products being pooled into size- and label-specific 
sets before analyzing. Markers were geno typed  on an ABI 3730 DNA analyzer 
(Applied Biosystems) using the G eneM apper 4.0 software package (Applied 
Biosystems). Allele binning was perfo rm ed using the Excel 2000 (Microsoft) 
macro Linkage Designer developed by Van Cam p et al. (19). Multipoint LOD 
score, pedigree check  and haplotype analyses of microsatell ite markers and 
SNPs were performed using Merlin, version 1.1.2 (21) and visualized using the 
Haplopainter software (22).
Candidate gene sequencing
Identif ication of known protein cod ing genes in the linkage interval was achieved 
through the National Center for B io techno logy Information (NCBI) and UCSC 
genom e browsers (Feb. 2009 (GRCh37/hg19)). Cand idate genes located in the 
linkage interval were sub jected to b idirectional DNA sequenc ing of the coding 
exons and ad jacent intronic sequences in 4 family m em bers  with a FMR1 
premutation (2 affected with POI ( indiv iduals II:1 and II:3) and 2 non-affected with 
POI ( indiv iduals II:11 and II:13) using standard m ethods (23). As of yet, two 
candidate genes were selected: PDE8A (phosphod iesterase 8A; NM_002605.2), 
and CYP19A1 (cytochrome P450, family 19; NM_031226.2). Primer sequences 
and PCR cond it ions are available upon request.
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Results
C lin ica l characteris tics o f FXPOI fam ily mem bers
All 8 affected w om en and their 2 unaffected sisters were (obligate) carriers of an 
FMR1 premutation of paternal origin. The eldest of the 10 sisters (Figure 1; II:1) 
had a late menarche and an irregular cycle (23-45 days), with normal fertility. She 
never used oral contraceptives (OC) and conceived 7 children with a few irregular 
menstrual cycles after her last delivery. At age 36 she becam e postmenopausal.  
Indiv idual II:2 had regular cycles with normal fertility. After her second 
uncom plica ted delivery she had no menstrual periods and started OC use. During 
OC use she becam e pregnant and after her third delivery am enorrhea occurred 
at the age of 34 years. Individual II:3 had menarche at 14 years of age and regular 
cycles with normal fertility. After her third delivery am enorrhea occurred for 2 
years. After 2 years she had one final period and becam e postm enopausa l at the 
age of 31 years. After menarche at the age 15 of years indiv idual 11:5 had regular 
cycles. Initially, sub-fert il ity  occurred (>24 months to conception), but her second 
p regnancy was established with in 6 months. A m enorrhea occurred at age 35 
years of age. After a normal menarche and regular cycles, indiv idual II:7 started 
OC use at the age of 34 years. At the age of 39 years she was steri lized and she 
had her final menstrual period a few months later at the age of 39 years. Individual 
II:8 had irregular cycles (3-7 weeks) after menarche at the age of 14 years. She 
had normal fertil ity and started OC use after her third child was born at the age of 
29 years. At the age of 34 years she forgot her OC for several days and waited for 
her period, wh ich did not come. She restarted OC use after 2 months. After 
cessation of OC use at 38 years of age amenorrhea occurred for more than 1 year 
wh ich conf irmed her postm enopausa l state. For indiv idual II:9 menarche occurred 
at age 16 years with regular cycles until 20 years of age when irregular cycles 
com m enced. At the age of 23 years she started OC use and she d iscontinued 
this use at the age of 34 due to d im inished b lood loss after wh ich amenorrhea 
occurred. She was seen by a gyneco log is t  who perfo rm ed a d iagnostic  
laparoscopy confirm ing her postm enopausa l state by the presence of small 
ovaries and the absence of follicles in the biopsy. Individual II:11 had her menarche 
just before her 15th b ir thday with regular cycles and normal fertility. After her 
children were born she used OC for 2 years and was steri lized at the age of 29 
years. At the age of 48 she becam e postmenopausal.  Indiv idual II:12 had regular 
cycles from 15 to 18 years, after wh ich irregular cycles (25-90 days) com m enced. 
At the age of 23 years she had her final menstrual period. She had a d iagnost ic  
laparoscopy revealing small ovaries w ithout fo ll icular activ ity  upon biopsy. 
After normal menarche and regular cycles, indiv idual II:13 s topped having 
per iods at the age of 43 years. Two years later she had a final period. The mother
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Table 1 S u m m a ry  of clin ical data from  affected fam ily  m em bers of POI fam ily
Individual A ge at Cycles (days) M enarche
am enorrhea
2 NMA Unknown Unknown
:1 36 Irregular (23-45) 16
:2 34 Regular (28) 14
:3 31 Regular (30) 14
:5 35 Regular (30) 15
:7 39 Regular (28) 14
:8 38 Irregular (21-60) 14
:9 34 Regular (28) 16
:11 48 Regular (30) 14
:12 23 Regular (28) 15
:13 45 Regular (28) 13
NMA: no medical record available; *fertility defined as months of unprotected intercourse with the intention to conceive.
(ind iv idua l I:2) had 13 ch ild ren of w h o m  2 died sh o rtly  a fte r b irth  due to  unknow n 
cause. H er m eno p ausa l age is unknow n, but in her fo rtie s  she gave b irth  to  3 
ch ild ren, her last child  at the  age of 45 years, m aking  ovarian insu ffic iency  from  
m aterna l orig in  ve ry  unlikely. N one of the  daug h te rs  from  these  e igh t FXPO I 
a ffected  w om e n  had m eno p ause  at young  ages. In Tab le 1 the  cha rac te ris tic s  of 
th is  fa m ily  are listed. No d ysm orp h ic  fea tu res  assoc ia ted  w ith  the  occurrence  of 
the  ovarian  insu ffic iency  w ere noted in th is  fam ily.
Linkage and haplotype analysis reveals a candidate locus on chrom osom e 15
A g en o m e -w id e  linkage ana lys is  using an A ffym e trix  G eneC h ip  250K  (Nsp I) SN P 
a rray p la tfo rm  w as perfo rm ed . By do ing  so, one p os itive  linkage signa l w ith  a 
m u ltip o in t LOD score of 2 .387 w as observed  in a reg ion of 7.54 Mb in size on 
c h ro m o so m e  15 (F igure 2) rang ing  from  S N P  A -2092428  (79.61 Mb) to  SN P 
A -2106264  (87.15 Mb). The  una ffec ted  ind iv idua l II:13 a lso  ca rries  the  d isease 
hap lo type , except fo r a sm a ll sub -re g ion  of 3 .38 Mb (SN P A -2181330 and SN P 
A-1872840). E ight m ic rosa te llite  m arkers, D15S131, D 15S1023, D15S1041, 
D15S206, D15S205, D15S154, D15S152, and D15S127, w ere se lec ted  betw een 
positions 71.81 to 91.39 Mb to confirm  the data obtained through the SN P analysis. 
Two of these  m arke rs w ere loca ted  in the  sm all 3 .38 Mb sub -reg ion . Using 
m ic rosa te llite  ana lys is , it w as indeed con firm ed  th a t the  large 7.54 Mb reg ion w as 
linked to  the  d isease  and d im in ished  the  sub -re g ion  to  2.11 Mb (SN P A -2181330
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Fertility* Num ber A ge at A ge at FMR1
(months) o f children first child last child C G G  repeat
<6 13 25 45 30/32
<6 7 25 36 30/82
<6 3 29 34 32/74
<6 3 26 31 30/73
36 2 30 32 30/75
<6 4 27 32 32/101
<6 3 26 29 30/83
>24 0 - - 30/80
<6 2 23 25 32/75
unknown 0 - - 32/65
<6 2 24 27 32/84
# -  D15S154). Hap lo type construct ion of the com b ined  SNP and microsatell ite 
linkage analysis data is shown in Figure 3. In addition, a recombinat ion was 
observed in indiv idual II:8. This recombinat ion did not delimit the linkage interval. 
The recom binat ions observed in indiv iduals  II:1 and II:12 through SNP analysis 
were also conf irmed by the microsatell ite analysis.
Candidate gene se lection and sequencing
The linkage interval found on chrom osom e 15 contains ~74 annotated genes, at 
least 35 of wh ich are protein coding. To identi fy  a potential FXPOI modifier, we 
selected from the 35 protein cod ing genes putative cand idates known to be 
associa ted with oogenes is  and/or foll iculogenesis . Two of these genes had a 
direct functional link to reproduction. The first one, PDE8A, encodes p h o s p h o ­
diesterase wh ich regulates in tracellular levels of cAMP and cGMP. A recent animal 
study showed that the PDE8A protein is one of the predom inant ly  active PDE’s in 
oocytes and is involved in the regulation of fo l l icu logenesis (24). Others have 
hypothesized that human PDE8A  may serve as a PCOS candidate gene, but firm 
evidence for such a role is as yet still lacking (25). The second candidate gene is 
CYP19A1. A s ignif icant association with POI was found for a SNP in the CYP19A1 
gene by others (26). CYP19A1 cata lyses the b iosynthesis  of all oestrogens from 
androgens (27;28). Even though  CYP19A1 is located just outs ide our candidate 
region on chrom osom e 15, its reported association with POI turned this gene into
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Figure 2 Results of the genome wide linkage analysis: Multipoint LOD score are indicated in the Y axis and chrom osom es are 
displayed in the X axis
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Computations were done in sets of 50 markers with R2 =0.05.
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Figure 3 Haplotypes based on SNP and microsatell ite genotypes delineated 
a critical region ranging from SNP A-2092428 (79.61 Mb) to SNP 
A-2106264 (87.15 Mb)
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The unaffected individual II:13 also carries the disease haplotype, except for a small sub-region of 2.11 
Mb (SNP A-2181330 and D15S154). Genotypes from I:1 and I:2 were inferred. Physical position (Mb) of 
each marker is shown according to NCBI build 37.1.
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an interesting candidate. DNA sequenc ing of all cod ing exons and exon-intron 
boundaries of these 2 candidate genes was perfo rm ed in 4 FMR1 premutation 
carriers: 2 affected with POI ( indiv iduals II:1 and II:3) and 2 non-affected with POI 
( indiv iduals II:11 and II:13). By doing so, no causative sequence variants were 
identif ied in PDE8A in all 4 tested females. In CYP19A1 several intronic variants 
were identif ied, but only in single indiv iduals  each. Since these variants are not 
shared between affected and non-affected females, for the t ime being they are 
excluded as modif ie rs for FXPOI.
Discussion
The genom e-w ide linkage analysis reported here is based on the hypothesis that 
modif ier loci for FXPOI susceptib il i ty  may be at work in FMR1 premutation carriers. 
To our knowledge, we here report the first genom e-w ide linkage analysis aimed at 
identifying such a locus. Hunter et al. (29) showed that after correction for the FMR1 
premutation, additional genes may contribute to a variation in age at menopause. 
We hypothesize that these putative additional genes may contribute to the 
susceptib il i ty  of a premutation carrier to develop FXPOI. In this respect, several 
options are possible. Firstly, a POI susceptib il i ty  gene could coincide with the FMR1 
premutation, as reported by Miano et al. (30). They reported the co-existence of two 
dysfunctional ovarian conditions within the same family, one FMR1-related and one 
FMR1-unrelated. In famil ies like this, POI is expected to be found in subsequent 
generations regardless of carrier status of FMR1 premutation alleles. In the present 
family, the daughters (N=12) from the 8 affected wom en were either full mutation 
carriers or non-carriers. At interview, aged 34 to 51 years, none of these daughters 
had reached menopause. Because of prolonged hormone use or young age 5 
daughters were uninformative with respect to natural menstrual cycles. The 7 
informative third generation women, 2 full mutation carriers and 5 non-carriers, still 
had normal menstrual cycles at ages 34, 36, 37, 47, 48 (two females) and 51, 
respectively, although the two eldest wom en experienced irregular cycles. Though 
the three youngest wom en can theoretically still reach menopause before 40 years 
of age, their early fol licular FSH and AMH levels were in the normal range (<10IU/l 
and >1.2 ng/ml, respectively). The presumed lack of menopausal ages before 40 
years in this generation makes an isolated id iopathic POI locus unlikely.
A second option is that an independently segregating gene could infer susceptibili ty 
for POI associated with the FMR1 premutation and its penetrance by acting as a 
modifier. It has been reported that FXPOI may show familial clustering and segregation 
(6;13;14;30;31). In several familial FXPOI cases mothers, daughters and/or sisters, all 
carrying premutations, were found to be affected (31 ;32). In the current family, all
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daughters inheriting the maternal premutation showed expansion to a full mutation. 
The prevalence of familial versus isolated FXPOI is unknown. Recently, we found that 
28% of FMR1 premutation carriers in fragile X families developed FXPOI. Of these 
women, 60% appeared to be the sole affected in the family, whereas 40% had at least 
one other first or second degree affected relative (unpublished data). In case a 
genetic modifier is involved in the development of FXPOI, as is suggested from the 
data in the current family, its identification is anticipated to lead to information about 
the pathogenic mechanism underlying FXPOI and to the cellular pathway(s) involved. 
This information could also have broader clinical implications in case the mutation or 
variant is not private, it may have consequences for individual risk assessment for 
FXPOI among FMR1 premutation carriers.
In the present genom e-w ide  linkage analysis for FXPOI in a large family with 8 
affected sisters, a substantia l linkage signal was observed at ch rom osom e 15q25. 
This signal showed a LOD score of 2.387 in a 7.54 Mb region (extending from 
posit ion 79.61 to 87.15 Mb). The theoretical possib le m axim um  LOD score in this 
family is 2.4. Since the unaffected indiv idual II:13 carries the disease haplotype, 
we assume that this case presents with a reduced penetrance. However, it is also 
possib le that the modif ie r gene is located in the small region of 2.11 Mb (SNP 
A-2181330 and D15S154), that is recom bined in indiv idual II:13.
The sequenc ing of candidate genes in this region did so far not yield any genetic 
variants that could be linked to the disorder. Very recently, a genom e-w ide  copy 
num ber profi ling study led to the identi fication of several candidate POI regions 
on the human genom e (33). One of these regions exactly co inc ides with our 
linkage interval on chrom osom e 15, thus corroborat ing our current findings. This 
region encom passes  yet another interesting candidate gene, CPEB1. Previously, 
knockout mice have revealed that CPEB1 may contro l germ cell differentiation 
(34) and another animal s tudy has shown that CPEB1 regulates meiotic  resumption 
in oocytes (35). The putative involvement of this novel candidate gene is currently 
under investigation. It is very well possib le, however, that the modif ie r gene has 
an as yet unknown function in oogenes is  and/or foll iculogenesis . As an alternative, 
we therefore propose to re-sequence all genes in the linkage interval using high 
th roughpu t next-generation sequencing. This novel techn ique allows the 
assessm ent of the entire candidate region in one single test. The simultaneous 
assessm ent of an affected indiv idual and an unaffected indiv idual with an 
overlapping paternal allele for this interval (e.g. II;5 and II;11) will s ignif icantly  
reduce the num ber of variants that need to be validated, i.e., variants present in 
only the affected indiv idual can be cons idered as possib le modif iers. Alternatively, 
in case no modif ie r is identi fied this way, the data can equally well be used to 
search for putative protective variants (i.e., variants that are un iquely present in 
the unaffected individual).
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Identification of a new locus for primary ovarian 
insufficiency on chromosome 3p25.1-3p24.3
#Chapter 6
Abstract
Background: Primary ovarian insuff ic iency (POI) is a condit ion characterized by 
cessation of normal ovarian function before the age of 40, defined by amenorrhea 
of at least 4 months and high levels of follicle st imulating hormone (FSH above 40 
IU/1). Previously, famil ial aggregat ion of POI has been reported by several groups 
and it was found to vary from 4% to 31%. Here, we clinically and genetically 
characterized a large Dutch family with POI.
M ethods: A genom e w ide linkage scan was perfo rm ed in a family with 7 women 
with POI in two successive generations using Illumina microarrays contain ing 
300K single nucleotide po lym orph ism s (SNPs).
Results: Linkage analysis revealed a novel candidate POI locus on chrom osom e 
3p25.1-3p24.3 with a suggestive LOD score of 2.7. This locus contains several 
genes that are expressed in ovaries. Sequencing of one candidate gene within 
this locus, IQSec1, did so far not reveal any causative variants.
Conclusion: G enom e w ide linkage analysis in a large Dutch family with POI 
revealed a novel candidate suscept ib i l i ty  locus on chrom osom e 3p25.1-3p24.3.
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Introduction
Primary ovarian insuff ic iency (POI) is a condit ion characterized by cessation of 
normal ovarian function before the age of 40, defined by am enorrhea of at least 4 
months and elevated FSH levels (above 40 IU/1). This he terogeneous condition 
encom passes  both pr imary and secondary  amenorrhea. POI has previously been 
referred to as premature menopause or premature ovarian fai lure (POF). The 
preferred term now is pr imary ovarian insuff ic iency (POI) (1;2) because of 
intermittent ovarian function in 50% of the patients (3-5) and a 5-10% life-time 
chance of pregnancy (6).
Its heterogeneous character suggests  more than a single pathogen ic  mechanism. 
This notion has been substantia ted by a w ide range of genetic and non-genetic  
causes identified. Genetic causes can be grouped into gross chrom osom al 
abnormali t ies (deletions and translocations) and subtle genetic alterations (GALT, 
FMR1 gene mutations and FSHR po lymorphisms). The non-genet ic  causes can 
be grouped into au to im m une d iseases (auto immune lym phocytic  opphorit is , 
au to im m une po lyg landu lar syndrome), in fections (mumps) and iatrogenic causes 
(after bilateral oophorectomy, chem otherapy  or radiation). Together, however, 
these causes explain only  a small p roport ion of POI cases. The etio logy of the 
majority of the cases, therefore, remains unknown and they are referred to as 
id iopathic  POI. The prevalence of famil ial POI varies from 4% to 31% (5;7;8) of the 
id iopathic  POI cases. In cases of famil ial aggregation, linkage analysis can be 
em ployed as a useful method to identi fy  potential novel genetic  causes and/or its 
related cellu lar signaling pathways.
As yet, only a few POI linkage studies have been reported. This is due to the fact 
that proper well-character ized famil ies with multiple affected indiv iduals  are 
required. Such famil ies, however, are scarce due to the intrinsic reproductive 
problems. Susceptib i l i ty  loci have been identified using linkage analysis for POI 
on chrom osom e 5 (9) and for early menopause on chrom osom es  9 and X (10). In 
addition, susceptib i l i ty  loci on ch rom osom es  8, 11 and 16 have been reported 
using age at menopause, early menopause or POI as a trait (11).
Here we report a large Dutch family with 7 patients affected with POI and 4 
patients with early menopause in two  successive generations. In this family, we 
perfo rm ed a genom e w ide linkage analysis and, by do ing so, identified a novel 
candidate POI locus on chrom osom e 3p25.1-3p24.3.
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Material and methods
Subjects
A large Dutch family with 7 w om en affected by primary ovarian insuff ic iency (POI) 
was ascerta ined th rough the Departm ent of Obstetr ics and G ynaeco logy  of the 
Radboud University Ni jmegen Medica l Centre, the Netherlands. Medical histories 
on general health and reproduct ion were taken by one physic ian (MS). Medical 
records were retr ieved when available. B lood sam ples for DNA isolation and 
cy togenetic  analysis (index case) were col lected after obtain ing wri tten informed 
consent. POI was defined accord ing  to the fo llowing criteria: at least 4 months of 
am enorrhea and at least one FSH determ ination above 40 IU/l. In case of absence 
of in formation on FSH levels, com p le te  cessation of menstrual periods before the 
age of 40 was appl ied as criterion for POI (in absence of other causes of 
amenorrhea). Figure 1 depicts  the pedigree of this family, including 7 cases with 
POI and 4 cases with early menopause, in two  generations. The inheritance of the 
disease is com pat ib le  with an autosomal dom inant pattern. Yet, based on the 
disease segregat ion in the family, a X-linked dom inant pattern of inheritance 
could not be excluded.
SNP and haplotype analyses
G enom ic  DNA was isolated from peripheral b lood cel ls using a Chem agic  
Magnetic  Separation Module 1 (Chemagen) fo llowing standard procedures. 
Genom e w ide linkage analysis was conducted  using DNA from 14 m em bers of 
the family, including 7 POI patients. In addition, two females with early m enopause 
were inc luded in the linkage analysis as affected because they had daughter(s) 
with POI. Females with incomplete data or p ro longed horm one use, as well as 
females younger than 40 years, were inc luded in the analysis as ‘d iagnosis 
unknow n ’. Human CytoSNP12 microarrays contain ing 301,230 SNPs were used 
and the sam ples were processed accord ing  to the m anufacture r ’s instructions 
(Infinium DNA analysis BeadChip kits, Illumina). The G enom eStud io  Data Analysis 
software package (Genotyping module) was used for geno type cal ling, quality 
control and export of the data.
Microsatell ite markers m app ing to the identified genom ic  regions were selected 
to confirm the POI-associated haplotype. Polymerase chain reaction (PCR) 
products  were run on an ABI Prism 3130x/ genetic  sequencer (Applied Biosystems) 
and analyzed using the G eneM apper software v.3.0 package (Applied Biosystems). 
DNAs from 23 available family m em bers were genotyped.
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Figure 1 G enealogical tree of the POI family.
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Linkage analysis and locus identification
The statistical package EasyLinkage Plus v5.08 (12) designed to perform 
automated linkage analyses using la rge-scale SNP data, was em ployed to 
perform all analyses. All SNPs showing inconsistency in t ransm iss ion were 
removed from further analyses. The Allegro v1.2c software package (incorporated 
in the EasyLinkage Plus v5.08 package) was used to perform fully automated 
single poin t and multipoint linkage analyses. LOD scores were obta ined using a 
dom inant model of inheritance, with a penetrance of 95% and a d isease allele 
frequency of 1:1,000. Allele frequencies of geno typed  SNPs were set to 
co-dom inan t.  M ap  order and inter-SNP d is tances were taken from the Il lumina 
website. Since closely  spaced SNP markers were used, the linkage analyses were 
performed with a predefined spac ing of 0.3 to 0.15 cent iMorgan (cM) in b locks of 
90 and 100 SNPs. Single ch rom osom es  showing posit ive linkage were 
independently  analysed under the same cond it ions and haplotypes were 
constructed. G raph ica l visualization of haplo types to facil itate inspection and 
analyses was perfo rm ed with HaploPainter v029.5 (13), a tool for drawing 
pedigrees with com p lex  haplotypes.
Sequence analysis
Direct sequenc ing of the entire cod ing region and the exon-intron boundaries  of 
posit ional candidate genes was undertaken using PCR primers designed by 
Primer3 software. Amplif ied PCR products  were purif ied and sequenced using 
BigDye Terminator chemis try  v3.1 on ABI Prism 3100 and 3130x1 genetic analyzers 
(Applied Biosystems). Sequences were al igned and com pared  with consensus 
sequences obtained from human genom e da tabases (NCBI, UCSC) using the 
App lied Biosystems software package SeqScape v2.5.
Results
Clinical characterization of a novel two-generation POI family
A Dutch POI family with 7 wom en with POI in two  successive generations, showing 
a dom inant pattern of inheritance w ithout overt antic ipation was ascerta ined. The 
proband of this family (Figure 1, III:25) presented at age 30 years with secondary  
infertility of 12 months. Menarche occurred at age 13 with regular cycles (30 days). 
Oral contraceptives were used from age 17 to 27 and, after d iscontinuation, she 
spontaneous ly  conceived, wh ich ended in a miscarriage. After this m iscarriage 
secondary  infertil ity occurred. Because FSH levels were mildly  elevated (10 IU/l 
and 17 IU/l), hyper-st imulation with c lom iphene citrate was started and this 
treatment resulted in p regnancy and a live birth. A year later, she exhibited a
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normal FSH level and spontaneous ly  conceived again. After her second delivery 
cycle irregularity com m enced  and FSH levels were postm enopausa l (84 IU/l, 95 
IU/l) with a thin endom etr ium  and ovaries w ithout fo ll icular activ ity  upon ultrasound 
examination. At age 35, am enorrhea occurred. Cytogenetic  analysis of peripheral 
leucocytes showed a normal female karyotype (46,XX) and DNA analysis 
indicated that she did not carry a fragile X premutation (CGG repeat length 32/33). 
Thyroid and adrenal functions were normal. The mother of the proband (II:7) had 
regular cycles with normal fertility. After her third uncom plica ted delivery she had 
one menstrual period before am enorrhea occurred at age 34 years. The mother 
of the proband had 7 sisters of whom  one had POI and 3 had at least early 
m enopause (see Table 1). The sister with POI (II:8) had 3 children and irregular 
cycles varying from 21 to 35 days. After her third uncom plica ted delivery 
am enorrhea occurred and 6  months later she had one final menstrual period 
before she becam e postm enopausa l at age 35. Indiv idual II:1 had irregular cycles 
and vasom otor  sym ptom s at age 32 for wh ich she started hormone treatment. 
She presented with am enorrhea at age 44, after cessation of the hormone 
treatment. Indiv idual 11:6 had regular cycles with sudden am enorrhea at age 44 
and indiv idual II:10 had regular cycles with irregular menstrual cycles for 1 year 
before becom ing postm enopausa l at age 44. In two sisters of the p ro b a n d ’s 
mother no proper clinical d iagnos is  could be made: one sister (indiv idual II:13) 
had m enopause at age 37, probab ly  iatrogenic, due to chem otherapy and 
radiation for breast cancer and another sister did not exactly recall her age at 
m enopause (individual II:2). Her medica l record was uninformative on menopause 
as well. Only one aunt of the proband (II:9) was clearly unaffected and had her 
m enopause at age 49. The menopausa l age of the g randm other of the proband 
on her m o the r ’s side was unavailable, but she had 13 children of wh ich the 
youngest was born at maternal age of 41 years. The sister of the proband 
(indiv idual 111:26) had irregular cycles and an elevated FSH level (35 IU/l) at age 
34. She started oral contraceptives (OC) because of vasom otor sym ptom s and 
later switched to a progeste rone-con ta in ing intrauterine device. She presented 
with am enorrhea at age 40. The proband had 4 cousins (indiv iduals III:2, III:20,
111:22 and 111:27) d iagnosed with POI at ages 36, 37 and 39 (twice) years. Two 
additional cousins are currently under medica l follow-up: subjects III:28 and III:34, 
because they had elevated FSH levels (21 IU/l and 23 IU/l) and low AMH levels 
(0.42 ng/ml and 0.22 ng/ml) at ages 35 and 36 years, respectively. None of the 
examined family m em bers  presented with any obvious dysm orph ic  features. A 
sum m ary  of the clinical data of all family m em bers with POI or early m enopause 
is provided in Table 1.
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Table 1 Summary of clinical data from [affected] family m embers of POI family
Individual A ge at 
am enorrhea
FSH (IU/l) M enarche
I:2 NMA NMA Unknown
II:1** 44 NMA 12
II:6** 44 NMA 14
II:7* 34 NMA 14
II:8* 35 NMA 14
II:10 44 NMA 16
III:2* 39 105 at age 39 12
III:20* 39 79 at age 39 13
III:22* 37 63 at age 36 10
III:25* 35 10 and 17 at age 30 
95 and 84 at age 34
13
III:26 40 35 at age 34 14
III:27* 36 84 and 71 at age 36 14
NMA: no medical record available, NA: not analyzed, # : fertility defined as months of unprotected intercourse.
*: individuals included in linkage analysis, * *  included in linkage analysis because they are mother of an affected daughter.
Linkage analysis reveals a novel POI locus on chromosome 3
We first exc luded the most prevalent genetic  POI causes, such as structural or 
numerical chrom osom al abnormali t ies or a FMR1 premutation, in two affected 
females from the family. Then, a genom e w ide search using 300k SNP microarrays 
was initiated in 14 m em bers of our POI family. Nine patients were cons idered as 
‘a f fec ted ’ in the linkage analysis (See Material and Methods).  Overall, 292,135 
SNPs remained after removing SNPs with low call rates (less than 90%) or with 
unlikely genotypes. After predefined inter-marker spac ing of 0.3, 0.2 and 0.15 cM 
further linkage analysis was performed on 8,908; 13,053 and 17,043 SNPs, 
respectively. This analysis revealed linkage to a single region on chrom osom e 
3p25.1-3p24.3 with a multipo int LOD score of 2.7 (Figure 2). An additional 
multipoint LOD score of 2.3 was seen on chrom osom e 20, but this score could 
not be confirmed in further analyses. Therefore, this latter finding is considered as 
false positive. Three other regions on chrom osom e 5, 19 and 22 with LOD scores 
of 1.40, 1.26 and 1.25, respectively, are cons idered irrelevant because these 
scores are be low the near-suggestive linkage criterion of 1.5 descr ibed by Lander
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Fertility#
(months)
N um ber o f 
children
Age at 
first child
Age at 
last child
Karyotype, 
FMR1 C GG  
repeat
<6 13 26 41 NA
<6 6 25 31 NA
<6 3 26 31 NA
6-12 3 28 33 NA
<6 3 32 35 NA
<6 2 27 28 NA
6-12 3 28 32 NA
>24 1 31 - 46,XX 
CGG 30/32
6-12 2 32 34 NA
12-18 2 31 33 46,XX 
CGG 31/32
<6 3 29 32 NA
>24 0 - - NA
and Kruglyak (13). Haplo type analysis using the SNP data showed that all 9 
a ffected patients inc luded in this analysis shared the disease-associa ted 
haplotype (data not shown).
Subsequently , microsatell ite markers m app ing  to the chrom osom e 3 region 
ranging from 12.62 Mb to 15.36 Mb (D3S3701, D3S3610, D3S3608, D3S1585, 
D3S3613) were assessed to independently  confirm the SNP-based haplotype 
data in all available family members. This assessment revealed that the disease- 
associa ted haplotype was shared by 11 patients (7 with POI and 4 with early 
menopause; Figure 3). Individual II:9 (menopause at age 49) and her two 
daughters  (unaffected at 40 and 42 years) were also carry ing the d isease-assoc i­
ated haplotype. The borders of the candidate region are dem arca ted by 
recom binat ions in patients III:22 (D3S3701, 12.6 Mb) and II:8 (D3S3613, 15.3 Mb). 
This genom ic  region (12.6 Mb to 15.3 Mb) contains 47 genes of wh ich 13 are 
pseudogenes (NCBI build 37.2). One of these genes, IQ S ecI, is highly expressed 
in brain, ovaries and several other t issues. IQ S ecI be longs to the BRAG family of 
prote ins (referred to as BRAG2) that are involved in endocytos is  at the plasma
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Figure 2 Results of the genome wide linkage analysis: Multipoint LOD scores are indicated on the Y axis and chrom osom es 
are displayed on the X axis
pLOD (MPT)
Marker coverage and chromosomes
Computations were done in sets of 100 markers and a spacing of 0.15 cM.
Figure 3 Haplotypes with microsatellite genotypes corresponding to chromosome region 3p25.1-3p24.3
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membrane (14). A direct functional link of IQ S ecI to the development of POI 
remains to be established, but it has been suggested that the promoter region of 
IQ S ecI contains putative transcription factor binding sites for FOXO1a, FOXC1, 
FOXL1 and FOXO3 (15). FOXO transcription factors have increasingly been linked 
to prevalent reproductive disorders (16;17) and POI (18). FOXO1 proteins have 
been related to follicle development and atresia in a murine model (19) and FOXC1 
has been related to primordial germ cell migration in a knockout mouse model, 
which showed diminished ovarian reserve but normal folliculogenesis (20). A 
mutant FOXL2 mouse showed normal growth factor expression in oocytes with 
normal development and maturation, but the ovaries eventually became 
progressively hypoplastic (21;22). Also, different FOXL2 mutations seem to lead 
to different ovarian phenotypes (i.e., primary or secondary amenorrhea) in 
patients with Blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) 
(23). FOXO3 is a pro-apoptotic molecule and causes global activation of primordial 
follicles in mouse ovaries, resulting in follicular depletion (24;25). Finally, a recent 
animal study showed that FOXO3 is expressed in ovarian follicles and induces 
apoptosis in granulosa cells, suggesting that it is a candidate for the initiation of 
follicular atresia (26). Sequencing of the coding region of IQ S ecI and the binding 
sites of FOXO1, FOXO3, FOXC1 and FOXL, however, did so far not reveal any 
causative genetic variants. Other candidate genes from the chromosome 
3p25.1-3p24.3 region are RAF1 and WNT7a. RAF1 is responsible for regulating 
cellular growth in ovarian cancer and has been associated with reduced apoptosis. 
An alteration in this gene may enhance apoptosis in ovarian cells and, thus, lead 
to POI (27;28). WNT7a is a member of the WNT family of proteins that regulates 
cell fate and other aspects of development. In particular, WNT7a plays an 
important role in the early stages of development of the female reproductive 
system (29). Yet another gene, SH3BP5, is highly expressed in testis and ovaries. 
Sequence analysis of these additional candidate genes is currently ongoing.
Discussion
Genetic factors underlying POI have been identified through various methods, 
ranging from classical cytogenetic analyses, which suggested an involvement of 
the X-chromosome (30-32) to the more recently developed genome wide 
association studies, which suggested a role for candidate genes such as 
ADAMTS19 (33) and PTHB1 (34).
A major difficulty in identifying causal genetic factors for POI is the assembly of 
homogenous patient cohorts. POI exhibits an intrinsic heterogeneous phenotype 
and comprises an age limit in its definition. Amenorrhea can present either as a
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primary event, with a variable degree of secondary sex characteristics or, more 
commonly, as a secondary event after an episode of menstrual periods and/or 
pregnancies. The age of onset varies widely from pubertal age up to 40 years old. 
Nonetheless within our family only secondary amenorrhea occurred. Also there is 
no consensus on how to regard early menopause (menopause < 45 years) in 
families with POI: as a late onset POI or an early onset of normal menopause? 
Nevertheless, we embarked on a genome wide linkage analysis using high 
density SNP microarrays in a large Dutch family with 7 patients fulfilling the 
diagnostic criteria for POI. Two cases with early menopause were included in the 
linkage analysis as affected since they both had daughters with POI, indicating 
that they were carriers of a causal genetic variant. Female relatives with imminent 
ovarian failure, but not fulfilling the diagnostic criteria of POI (individuals 111:28 and 
III:34), were excluded from the analyses. The resulting linkage analysis revealed 
one single candidate region (3p25.1-3p24.3) reaching a suggestive LOD score of 
2.7. We did not observe genetic linkage to any of the previously reported loci on 
chromosome 5, 14 and 18 (9), nor any of the currently known genes associated 
with POI, such as FOXL2 on chromosome 3 (23). Since the genes identified to 
date only explain a small percentage of all POI cases, it is anticipated that more 
genes and/or genetic variants may contribute to the POI phenotype, which is in 
conformity with its heterogeneous nature (2) and the widespread variation in age 
of onset. Haplotype analysis showed that at least one unaffected woman carried 
the disease-associated haplotype. A possible explanation for this discrepancy 
may be a reduced penetrance of the susceptibility locus. Overall, the dominant 
inheritance pattern and the high prevalence seen in our POI family are indicative 
for a monogenic cause.
In conclusion, we clinically and genetically characterized a large Dutch family with 
POI. We identified a novel susceptibility POI locus on chromosome 3p25.1-3p24.3, 
containing several candidate genes. The causal genetic variant(s) within this 
locus remains to be identified.
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7 General discussion
Since the development of (primary ovarian insufficiency) POI was first noted 
among FMR1 premutation carriers in the last years of the 20th century (1-4), this 
condition has been the subject of many studies. Most of these studies focused on 
its heterogeneous character and its reduced penetrance of approximately 20% 
epidemiologically (5-7), while other studies were aimed at gaining insight into the 
mechanism(s) underlying these phenomena, including the use of mouse models 
(8-11).
Although the exact pathogenic mechanism of FXPOI has remained elusive, it is 
generally assumed that processes related to premature exhaustion of the resting 
pool of primordial follicles do underlie this condition. Since during the past 
decades the reproductive time span of women has been reduced due to the 
postponement of child bearing, the identification of women at risk for FXPOI 
before disease manifestation and reduced fertility has become imperative. The 
development of complex traits such as FXPOI may depend on genetic, 
environmental, and reproductive factors. In this thesis the impact of several of 
these factors and its putative value as predictors for FXPOI were assessed. Based 
on this information a prediction model for FXPOI, including a flow-chart for 
counseling, is proposed.
7.1 Genetic, environmental and reproductive factors
Genetic factors
Theoretically, healthy females should exhibit a random (~50:50) inactivation of 
the maternal and paternal X-chromosomes. However, several studies have 
indicated that, depending on age, non-random X-chromosome inactivation (XCI) 
may be common in healthy females (12;13). Since XCI determines the phenotype 
in full FMR1 mutation carriers (14-16), and since skewed X-inactivation tends to 
normalize mRNA levels when the FMR1 CGG repeat size increases, it has been 
suggested that X-inactivation skewing may be involved in the manifestation of 
FXPOI (9). Based on XCI ratios at the FMR1 and AR gene loci among premutation 
carriers with FXPOI and premutation carriers without FXPOI, we report in chapter 
2 that skewed X chromosome inactivation is not associated with the development 
of FXPOI (and/or POI in general). Based on these findings, we have excluded XCI 
skewing as a predictor for FXPOI from further analyses.
Another putative genetic risk factor is the FMR1 CGG repeat size itself, for which 
an association with FXPOI has been reported by others (5;6;11). In chapter 3 we 
describe an approach through which hazard ratios for menopause at an early age 
by individual repeat size can be determined, referred to as “risk index by repeat
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size” (RIR). This approach has the advantage of not using an arbitrary classification 
where ± 1 or 2 repeats, based on methodological accuracy, has a notable impact 
on the risk ratio for women at the boundary of two groups. Instead, each repeat 
size has its own ratio with only small differences in that repeat area. By using this 
approach, RIR turned out to be an important predictor for menopausal age in 
FMR1 premutation carriers. Information on this predictor is available for all FMR1 
premutation carriers who need counseling, as it is routinely determined molecularly 
to diagnose the carrier status.
Another factor, mean menopausal age of first degree relatives with the same 
FMR1 mutation status, was hypothesized to act as a predictor because menopausal 
age in general is heritable (17;18), while Hunter et al. (19) showed that after 
correcting for effect of repeat size on menopausal age a substantial additional 
genetic effect is left. We reported a significant association of this genetic factor 
with menopausal age for both non-carriers and FMR1 premutation carriers in 
chapter 3. During our further modeling process, however (see below), we found 
that mean menopausal age of first degree relatives with the same mutation status 
did not significantly contribute to our FXPOI prediction model.
Environmental factor
The only non-genetic factor previously associated with menopausal age in FMR1 
premutation carriers is smoking, which was found to reduce age at menopause 
(5). By univariate and multivariate Cox analyses with robust estimation in the 
subgroups of FMR1 premutation carriers and non-carriers the association of 
smoking with menopausal age was assessed. In chapter 3 we describe that 
smoking is indeed a significant risk factor for early menopause in FMR1 
premutation carriers.
Though a number of epidemiological studies show both earlier menopause among 
obese women (20) and no significant difference in menopausal age for body-mass 
index (BMI) quintiles (21), BMI was assessed for its association with menopausal 
age in our study population in chapter 3. Through multivariate analysis, no 
association was observed with menopausal age in FMR1 premutation carriers.
Reproductive factors
The age at menarche has also been studied extensively by others (22-24), but 
only Cramer et al. (25) found early menarche to be associated with early 
menopause. Our assessment of age at menarche as a possible predictor in 
chapter 3, however, failed to reveal an association between age at menarche and 
menopausal age in FMR1 premutation carriers.
Although it has been documented that having none or only a few children may be 
associated with a higher risk for early menopause, and that a higher number of
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deliveries postpones menopause [Chang 2007], parity was not associated with 
menopausal age among the FMR1 premutation carriers described in chapter 3. 
A few studies have suggested that the use of OC may delay the onset of general 
menopause (26;27). However, De Vries et al. (28) only found a postponement of 
menopause for high dose OC, whereas several other studies did not show such 
an effect at all (29-31). An association with menopausal age in FMR1 premutation 
carriers has in the past not been tested. Our assessment of a relation between the 
use of OC and age at menopause indicated that OC use has no significant effect 
on age at menopause, at least not in our FMR1 premutation study population 
(chapter 3).
In contrast to the assessment of various genetic and reproductive factors relevant 
for general menopausal age, as environmental factor we could only associate 
smoking with menopausal age in FMR1 premutation carriers. This may be due to 
a small sample size, as the risk for early menopause described in the literature is 
often small and only evident in studies performed on large cohorts. As a corollary, 
however, these small effects on menopausal age will rarely be clinically relevant. 
Another possible explanation is that the observed lack of an association indicates 
that FXPOI is not just an early menopause, but rather a condition with a different 
pathophysiology and its own inherent risk factors, even after correcting for the 
effect of the FMR1 CGG repeat size.
A significant association of a (genetic) factor with menopausal age among FMR1 
premutation carriers does not automatically define this factor as a suitable 
predictor. To this end, multivariate analyses, correcting for the impact of other risk 
factors, are required to confirm the association. Overall, risk factors can be 
categorized into three groups: I) factors that are poor predictors for FXPOI, i.e., 
XCI, OC use and age at menarche; II) factors that are good predictors for FXPOI, 
i.e., FMR1 CGG repeat size and smoking; III) factors that may be associated with 
menopausal age in FMR1 premutation carriers based on their involvement in 
ovarian function and/or ovarian reserve, or genes involved in polygenic variance 
as seen in menopausal age.
7.2 A FXPOI prediction model
Inclusion of the most relevant predictors as described above has led to the 
development of a preliminary prediction model (chapter 3) generating probability 
estimates for FMR1 premutation carriers to become postmenopausal at a certain 
age with an accuracy of up to 7-10 percent. This prediction model is based 
on FMR1 CGG repeat size and smoking and, in addition, a correction for 
ascertainment site.
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The strength of this FXPOI prediction model is the possibility to generate a 
personalized risk estimate, instead of a generalized 13-26% prevalence as 
described in the literature for FMR1 premutation carriers. Another strength is the 
way of presentation of the risk estimates, as is also the ability to relate risk 
estimates to the onset of FXPOI. A 20% chance of having FXPOI at 30 years of 
age is more informative than an overall 30% chance of having FXPOI. A putative 
weakness of this model is the fact that geographic location seems to have an 
effect on menopausal age and, thus, needs to be included in the model. Such an 
effect by ascertainment site hampers general applicability and, thus, requires 
improvement of the model before clinical implementation.
The ultimate goal of these risk assessments is to personalize management 
strategies for all FMR1 premutation carriers, with the aim to reduce the number of 
FMR1 premutation carriers that remain involuntary childless. Reduced fertility 
may result from the inability to get pregnant spontaneously or the ineligibility for 
IVF combined with pre-implantation genetic diagnosis (PGD). Additionally, in 
cases where PGD is performed a poor response to hormone stimulation or 
implantation failure could still hinder pregnancy for premutation carriers.
Based on both genetic and environmental data, we have developed a preliminary 
FXPOI prediction model that, before it can be implemented clinically, requires 
further development. We anticipate that a more extensive assessment of the 
currently used predictors, without the bias seen in our study and assessment of 
other potential predictors, will improve the accuracy of the model. This notion 
leads us back to the third group of predictors: potential predictors.
Anti-Mullerian hormone as a potential predictor for FXPOI
In its current state, the FXPOI prediction model does not include any endocrine 
marker for ovarian reserve or ovarian function. This is due to the fact that our 
study population contained too few women with known endocrine markers that 
reached age at menopause. One comprehensive endocrine marker for the ovarian 
follicle pool, the anti-Mullerian hormone (AMH), is known to decline by age. For 
FMR1 premutation carriers not only their age, but also their FMR1 CGG repeat 
size determines the size of their follicle pool (32). Our measurement of AMH levels 
corrected for this age-related decline and for the largest risk factor for FXPOI, i.e., 
FMR1 CGG repeat size, yielded a modeled AMH level. The individual deviation 
from this modeled AMH level, referred to as standardized AMH value, could serve 
as a potential FXPOI predictor. In our study we showed an intra-individual stability 
of this standardized AMH value over time implying that, indeed, it could serve as 
a predictor (chapter 4). A longitudinal study of multiple AMH levels among young 
FMR1 premutation carriers until their forties should close the current gap in 
knowledge on the decline of the follicle pool in women who develop FXPOI, and
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reveal whether our standardized AMH value can be added to our prediction model 
as a valuable predictor for FXPOI.
Candidate gene approaches
A search for genetic factors modifying the phenotypic effects, including 
penetrance and onset, of the FMR1 premutation could further improve our 
prediction model. To this end, we performed a linkage analysis in a kindred with 
FMR1 premutation carriers with an excessive amount of FXPOI, inexplicable by 
the known prevalence of FXPOI. By doing so, we identified a candidate locus on 
chromosome 15 (chapter 5). A preliminary sequencing effort did so far not reveal 
any overt causative genetic variants. As yet, however, not all FMR1 interactions 
are known and, most importantly, the pathogenic mechanism of FXPOI is not fully 
comprehended. FMR1 premutation carriers show a reduction in FMRP levels and 
an elevation of FMR1 transcript (mRNA) levels. To assess this relationship mouse 
models with an expanded CGG repeat have been developed showing a similar 
increase in mRNA levels (33). These observations led to the hypothesis that 
FMR1 mRNA gain-of-function toxicity may cause reduction in ovarian reserve. 
A role for FMRP in this process is less likely due to the low prevalence of FXPOI 
among full mutation carriers who lack FMRP expression (1;4). The mouse FMR1 
gene showed high levels of expression in fetal ovaries but not in mature ovaries. 
This high expression was seen at the developmental stage where proliferation of 
oogonia takes place and, thus, it was suggested that FMR1 may control oocyte 
proliferation (34).
Allen et al. (8) showed elevated mRNA levels in female FMR1 premutation carriers 
and also Tejada et al. (11) confirmed that mRNA levels go up as the CGG repeat 
becomes longer. The expanded CGG premutation mRNA itself has been 
hypothesized to have a toxic effect on germ cells, thereby causing a more rapid 
depletion of the germ cell pool (5). This gain-of-function mechanism has also 
been suggested to underlie another FMR1 premutation-associated disorder, 
FXTAS. However, when correlating FXTAS mRNA levels to those of FXPOI, they 
do not seem to be associated with ovarian insufficiency and, therefore, this work 
has put the mRNA gain-of-function toxicity hypothesis into question. Elevated 
mRNA levels are not only seen in peripheral blood cells as mentioned above. 
Fontes et al. (35) recently evaluated the expression of FMR1 mRNA and FMRP 
in human granulose cells from FMR1 premutation carriers undergoing in vitro 
fertilization and found high levels of both at ovulation in granulose cells of FMR1 
premutation carriers.
Not only granulosa cells, but also whole ovaries of FMR1 premutation carriers 
have been evaluated morphologically by Sherman and Welt (S. Sherman, personal 
communication), revealing atretric follicles and intra-nuclear inclusions in stromal
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cells. These inclusions were only seen in one of the normal control ovaries and 
even then in small numbers, while ovaries of FMR1 premutation carriers may have 
up to 25 times more intra-nuclear inclusions. These intra-nuclear inclusions have 
also been seen in postmortem brain tissue from a man suffering from FXTAS 
(36;37). The content of the intra-nuclear inclusions currently identified included 
FMR1 mRNA and, in addition, many proteins, like mRNA-binding and 
mRNA-splicing proteins (37;38). There is debate about the effect of intra-nuclear 
inclusions on the development of FXTAS; the inclusions could either be toxic or, 
alternatively, have a protective effect by preventing expanded mRNA toxicity. As 
yet, however, the exact pathogenic effect on cell function of these inclusion bodies 
remains unknown as FMR1 mRNA and FMRP levels have not yet been assessed 
in human ovaries.
Cellular signalling pathways leading to an inadequate initial primordial follicle 
pool may be involved in the development of FXPOI, but also an accelerated 
expenditure of follicles can cause ovarian follicle depletion. Our current knowledge 
on the FMRP pathway is based on the lack of response seen in FMR1 knockout 
mice. FMRP and fragile X syndrome have been connected to the Gp1 GluR/FMRP 
pathway (39;40) and the Rac1 pathway in these mouse models (41). Gross et al. 
(42) recently connected the deficiency of FMRP to phosphoinositide 3-kinase 
(PI3K) pathway. Their results suggested that dysregulated PI3K signaling may 
underlie the synaptic impairments in FXS.
Candidate gene approaches may also lead to the discovery of novel genes that 
could contribute to POI susceptibility. However, the genetic heterogeneity of POI 
and the many developmental steps involved in ovarian insufficiency (see above 
and chapter 1) requires unbiased approaches such as genome-wide association 
studies (GWAS) and/or linkage analyses to point out candidate genes, instead of 
functional candidate- or pathway-related approaches.
Our linkage analysis in a Dutch family with POI revealed one candidate region 
located on chromosome 3 (chapter 6). Putative genes, regulatory and/or 
non-coding elements located within this region need to be assessed for possible 
functional clues. These assessments may be based on mutation, expression and 
functional information, i.e., expression in the ovary and/or relationships with genes 
involved in pathways known to be related to ovarian insufficiency, oogenesis, 
follicle development and atresia. As mentioned in the General Introduction of this 
thesis (chapter 1) a wide diversity of genes appears to be involved in the 
processes resulting in ovarian insufficiency. Some of these processes and genes 
are poorly characterized, whereas others are described in detail, such as the 
involvement of the FSHp subunit - activin pathway with various transcription 
factors which interact with FOXL (43;44) and the oocyte PTEN-PI3K pathway, 
which seems to govern follicle activation through control of initiation of oocyte
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growth (45). Based on its expression in ovaries, the region that we identified in 
chapter 6 yields one candidate gene (IQSec1). However sequencing of IQSec1 
did so far not reveal any causative genetic variants.
Other genetic approaches
In order to unambiguously identify genes associated with POI, candidate genes 
need to be sequenced to confirm and identify the genetic changes associated 
with the phenotype. Whenever linkage analysis yields large genomic regions and/ 
or many candidate genes, sequencing becomes cumbersome. The recent 
emergence of comprehensive methods to sequence whole genomes (also called 
next-generation sequencing) would provide a good alternative for these large 
candidate regions and holds the future for many genetic conditions.
In general, sequencing of whole genomes for gene identification requires a 
clinically well-defined and pure disease population. It will be very challenging to 
find a homogeneous population qualifying for whole genome sequencing, 
especially since POI is a heterogeneous condition defined by a cut-off age of 40 
years, based on the distribution of natural menopause, though biologically 
inexplicable. In addition, the definition is based on fluctuating hormone levels.
As yet, research aimed at genetic causes for POI has only provided an explanation 
for a minority of cases through genetic mutations and/or chromosomal 
abnormalities, as recently reviewed by de Vos et al. (46). Of the genes identified, 
FMR1 contributes most. The fact that despite many studies the majority of POI 
causes have remained unresolved suggests the existence of other, as yet 
unknown, genetic factors. Some of these factors may not represent traditional 
protein encoding genes but, instead, regulatory sequences and/or non-coding 
RNAs (47). Both GWAS and candidate gene approaches are based on the 
assumption that common variants underlie common diseases and traits. In order 
to apply this approach, POI should be considered an extreme of menopausal 
age, i.e., a common trait.
More likely is the possibility that low frequency genetic variants (CNVs and SNPs; 
frequency between 0.1 and 5%), also named rare variants, may contribute to the 
development of POI. These variants may also act as genetic modifiers and, as 
such, may contribute to disease susceptibility (48). Rare variants are often not 
captured by GWAS because of their low frequency. Thus, direct mapping is the 
way to detect these rare variants (chapter 5). This mapping has become feasible 
through the recent development of high-throughput SNP microarray and 
sequencing technologies.
Animal models can also be used to identify genes involved in the development of 
POI. Mouse knockout models, as reviewed by Jagarlamudi et al. (49), have gained 
insight into novel genes and putative factors in human ovarian pathophysiology.
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These genes function throughout various developmental stages, i.e., a FOXO3a 
knock out mouse model shows depletion of all follicles by 18 weeks due to over­
activation of the primordial follicle pool and a MSH5 knockout mouse model 
shows loss of oocytes at 2-3 months of age due to impaired chromosome 
synapsis (49). The large variety of genes involved in many different pathways 
leading to POI once again emphasizes the heterogeneous character of this 
disorder. Despite the extensive efforts made, as yet little of the information 
obtained has led to clinically relevant implementations. Only chromosomal 
abnormalities and the FMR1 premutation are currently recommended as 
diagnostic tests for women with POI. We, therefore, focused on the FMR1 
premutation to facilitate fertility counseling for these women through the 
development of a prediction model for FXPOI.
7.3 FXPOI prediction and clinical practice
As yet, FMR1 premutation carriers can only be informed about their general risk 
for reduced fertility at an early age and be advised not to postpone childbearing 
longer than necessary. Until now no attempts have been made to estimate the 
onset of FXPOI at a personalized basis. FXPOI risk estimates could facilitate the 
identification of FMR1 premutation carriers at high risk for FXPOI to offer them 
fertility preservation options. However, until very accurate risk estimates (probably 
including AMH serum levels) have been developed, one should opt for counseling 
all FMR1 premutation carriers before the age of 40 about FXPOI risk and fertility. 
This means that, besides counseling about the possibility of a child with fragile X 
syndrome and the pro’s and con’s of prenatal testing and PGD, these women 
should be referred to a fertility specialist to assess their ovarian reserve and 
discuss family planning and fertility preservation. However, care should be taken 
to present a balanced picture of the potential for reduced fertility in the context 
of life decisions and timing for reproduction as described for Turner syndrome 
(50). Although surveillance for the clinical onset of FXPOI remains difficult, multi­
disciplinary focus groups have recommended close medical follow-up for early 
signs of FXPOI (51).
For women with a partner and the wish to conceive, these couples have the option 
to attempt to conceive spontaneously either with subsequent prenatal testing for 
fragile X syndrome or without Fragile X diagnostics or, alternatively, they can 
apply for IVF combined with PGD. Oocyte donation and adoption are other 
options that should be mentioned when counseling these couples.
For women without a partner or with a partner, but no wish to conceive (yet) and 
considering to have children in the future, fertility preservation is becoming a
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realistic option. These, mostly younger, women could wait while yearly monitoring 
their ovarian reserve but, obviously, could also opt for fertility preservation 
techniques. One option to preserve fertility is cryopreservation of ovarian tissue; 
by laparoscopy, one ovary is removed. Subsequently tissue from the ovarian 
cortex, which is rich in oocytes, is sliced into cortical tissue strips. These strips 
will be cryopreserved and can later be reimplanted in the fossa ovarica or in the 
other ovary. This technique is still highly experimental. Proof-of-concept studies, 
however, have shown that many oocytes are lost during the process of freezing 
and thawing and therefore these techniques should still be considered as highly 
experimental.
Another option is freezing of mature oocytes. Initial results with conventional 
oocyte cryopreservation and thawing were poor due to problems with intracellular 
ice formation and the osmotic effect on the oocyte. Advances in cryopreservation 
techniques have led to the development of the ultra-fast freezing method known 
as vitrification.
Vitrification is a delicate modified process of programmed cryopreservation 
during which solidification of a solution occurs without the formation of ice 
crystals. This phenomenon requires either rapid cooling or the use of concentrated 
cryoprotectant solutions (52). After this technique was first used in animal models, 
human offspring has been produced using frozen-thawed oocytes as well (53;54). 
Although this fertility preservation method is still considered experimental, the 
success rates measured as both pregnancy rates and neonatal outcome have 
risen significantly, approaching those of standard IVF techniques using fresh 
oocytes (55). As a result, oocyte cryopreservation is currently regarded as a 
feasible option for fertility preservation.
Now fertility preservation becomes a serious option, the most favourable age 
needs to be determined. Young FMR1 premutation carriers could prefer to wait 
until they have a partner and outweigh prenatal tests and PGD together. Waiting 
too long, however, leads to low ovarian reserve and subsequent poor ovarian 
response after stimulation protocols and few oocytes (56). Because Tsafrir et al. 
(57) recently described ovarian function is the main determinant of success for 
PGD for FMR1 premutation carriers, we propose to start monitoring ovarian 
reserve of known premutation carriers as early as at 18 years of age, by yearly 
assessing FSH and AMH levels in serum, and antral follicle counts during the 
early follicular phase of the menstrual cycle.
Oocyte vitrification for FMR1 premutation carriers should preferably be performed 
at age 25, possibly extended to 30 years of age depending on the ovarian reserve 
present. A threshold level of adequate ovarian reserve for a sufficient oocyte 
retrieval after stimulation would certainly benefit application of the fertility 
preservation technique, but such a threshold level is currently unavailable and
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could be subject of future studies. Hopefully, in the future we will be able to 
provide reference values for either AMH, standardized AMH and/or AFC indicative 
for a high number of oocytes at oocyte-retrieval.
Caution should be taken in postponement of pregnancies, even based on a low 
risk for FXPOI. Our prediction model shows that it is possible to identify premutation 
carriers at high risk for FXPOI. This information, allows personalisation of their 
fertility counseling and where possible emphasize their possibilities for ovarian 
reserve monitoring and cryopreservation. Though pregnancies in women with 
FXPOI do occur rarely, these couples typically have the options of adoption and 
oocyte donation. For FMR1 premutation women at risk for FXPOI the chance for 
a child with fragile X syndrome complicates these decisions even more. It has 
been suggested that, when they are well-informed, premutation carriers will be 
less anxious and have a better quality of life (58-60).
Few follow-up studies have been conducted concerning the long-term effect of 
POI in general. Most women with POI use an hormone replacement therapy to 
prevent health problems. For example, oestrogen deficiency might lead to 
osteoporosis, with an increased lifetime risk of fractures (61). Cardiovascular 
disease has also been associated with early menopause and iatrogenic 
menopause after bilateral oophorectomy (62). Even though information on the 
direct effect of oestrogen replacement therapy for women with POI or FXPOI is 
still scarce, hormone replacement therapy is indicated (46).
Until our newly developed FXPOI prediction model is ready for clinical application, 
the main advice to young FMR1 premutation carriers remains not to postpone 
pregnancy longer than necessary.
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In the general population menopause Is reached around 51 years of age. However, 
approximately 1% of the women suffers from early ovarian senescence and 
develops primary ovarian Insufficiency (POI). In the past, various attempts to 
Identify the cause(s) of POI have been made, but as yet only a small proportion of 
POI cases can be explained. The most common heritable cause of POI represents 
a premutation in the FMR1 gene. Approximately 20% of female premutation 
carriers develop POI, referred to as Fragile X-associated primary ovarian 
insufficiency (FXPOI). The size of the premutation, i.e., the expanded trinucleotide 
(CGG) repeat in the FMR1 gene, is a risk factor for FXPOI. Also smoking has been 
shown to decrease menopausal age in FMR1 premutation carriers. However, 
additional risk factors for the development of FXPOI may improve the risk estimate 
and, thereby, facilitate counseling for FXPOI. In this thesis the suitability of genetic, 
environmental and reproductive parameters as modifying risk factors for FXPOI 
have been assessed, and a preliminary prediction model for the probability to 
develop FXPOI is proposed.
In chapter 2 we evaluated the role of skewed X chromosome inactivation (XCI) in 
the development of menopause before the age of 40 years among fragile X 
premutation carriers. For premutation carriers with FXPOI and without FXPOI 
similar skewed XCI ratios were seen, i.e., 19% of the premutation carriers with 
FXPOI showed skewed (>80:20) X chromosome inactivation and 17% of the 
premutation carriers without FXPOI showed skewed XCI. Also, the activity of the 
FMR1 premutation allele was similar. From these results we conclude that XCI is 
not important in the development of FXPOI.
In chapter 3 we assessed genetic and environmental factors as predictors for 
FXPOI by their association with age at menopause. Based on a large epidemio­
logical study among fragile X families and a general population cohort, several 
risk factors were assessed for their effect on menopausal age in FMR1 premutation 
carriers. The CGG repeat size showed the highest association with menopausal 
age (HR 1.43) for premutation carriers. Also smoking had a significant effect (HR 
1.34) on age at menopause for both premutation carriers and non-carriers. We 
developed a preliminary prediction model based on CGG repeat size, smoking, 
and mean menopausal age of first degree relatives (with the same mutation 
status). Based on this model, the probability of becoming postmenopausal at a 
certain age could be estimated with a margin of 7-10%.
In chapter 4 we assessed the potential of an ovarian reserve marker, anti-M ullerlan 
hormone (AMH), as a factor to develop risk estimates for FXPOI. The effect of age 
and premutation status were incorporated in a modeled AMH value. The deviation 
from this modeled AMH, referred to as standardized AMH value, showed a relative
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stability over time, as was shown by intra-individual correlation coefficients of 
0.36 for non-carriers and 0.69 for premutation carriers. Therefore, we conclude 
that standardized AMH may serve as a predictor for FXPOI.
In chapter 5 we used genome-wide linkage analysis to identify a FXPOI modifier 
susceptibility gene. By doing so, linkage to a locus on chromosome 15q25 was 
observed, with a multipoint LOD score of 2.39. This locus of 7.54 Mb in size (79.61 
Mb - 87.15 Mb) contained several candidate genes based on functional analysis 
in animal and human studies. A preliminary sequencing effort did so far not reveal 
any overt causative genetic variants. Another candidate gene within this locus, 
CPEB1, has recently been associated with POI and further analyses for a causal 
genetic variant is currently being performed.
In chapter 6 we report a linkage analysis in a large Dutch family with hereditary 
POI in two generations. A monogenic cause was considered most likely for this 
inheritance pattern. Our analysis yielded a locus on chromosome 3q25 with a 
LOD-score of 2.7. This locus contains several genes which are expressed, among 
others, in ovarian tissues. Sequencing of a candidate gene, IQSec1, did not reveal 
any novel genetic variants.
In chapter 7 all potential predictors for FXPOI assessed in this thesis and their 
relevance for the newly designed preliminary prediction model were discussed. 
To further improve our preliminary prediction model we suggest that AMH should 
be included. Though our linkage analyses did not reveal an evident modifier gene 
for FXPOI, further investigation of the newly identified chromosome 15q25 
candidate locus and/or other candidate loci could lead to the identification of one 
or more genetic modifiers for FXPOI that may serve as valuable parameters to be 
included in the prediction model.
Although the exact mechanism leading to FXPOI is still unclear, it has been 
suggested that elevated FMR1 mRNA levels may be involved. This suggestion, 
however, requires further investigation. Additionally, the identification of novel 
candidate genes associated with POI could provide valuable information on the 
etiology of POI, and thus be valuable for FXPOI. We conclude chapter 7 by 
emphasizing the importance of early identification of premutation carriers at risk 
for FXPOI for family planning.
In summary, this thesis reports that it is indeed possible to use a prediction model 
to estimate an individual’s risk for the development of FXPOI but that, at the same 
time, the complexity of this disorder requires improvement of the model before it 
can be applied in a clinical setting.
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In de algemene bevolking bereiken vrouwen gemiddeld op hun 51e levensjaar de 
menopauze. Ongeveer 1% van de vrouwen, echter, lijdt aan vroege ovariële 
veroudering en ontwikkelt primaire ovariële insufficientie (POI). In het verleden 
zijn verschillende pogingen gedaan om de oorzaken van POI op te helderen, 
maar tot op heden kan slechts een klein deel van de POI gevallen worden 
verklaard. De meest voorkomende erfelijke oorzaak van POI vormt een premutatie 
in het FMR1 gen. Ongeveer 20% van de vrouwen die draagster zijn van zo’n 
premutatie ontwikkelt POI, ook wel ‘Fragile X-associated primary ovarian 
insufficiency’ (FXPOI) genoemd. De grootte van de premutatie, een geëxpandeerde 
trinucleotide (CGG) herhaling in het FMR1 gen, is een risicofactor voor FXPOI. 
Daarnaast is aangetoond dat roken de menopauze leeftijd in FMR1 premutatie 
draagsters vervroegt. Echter, bijkomende risicofactoren voor het ontwikkelen van 
FXPOI kunnen de risicoschattingen, en daarmee ook de counseling, van FXPOI 
verbeteren. In dit proefschrift zijn de geschiktheid van genetische, omgevings en 
reproductieve parameters als modificerende risicofactoren voor FXPOI 
onderzocht. Op basis hiervan wordt een voorlopig predictiemodel voorgesteld 
voor het voorspellen van de kans op het ontwikkelen van FXPOI.
In hoofdstuk 2 evalueerden we de rol van ongelijk verdeelde X chromosoom 
inactivatie (XCI) in de ontwikkeling van menopause voor het 40e levensjaar bij 
fragiele X premutatie draagsters. Premutatie draagsters met en zonder FXPOI 
lieten dezelfde scheve verdeling in XCI ratio’s zien, namelijk 19% van de premutatie 
draagsters met FXPOI had een scheef verdeelde (>80:20) X chromosoom 
inactivatie en dit werd ook gezien bij 17% van de premutatie draagsters zonder 
FXPOI. Daarnaast was het FMR1 premutatie allel in dezelfde mate actief. Deze 
resultaten leiden tot de conclusie dat XCI geen belangrijke rol speelt in de 
ontwikkeling van FXPOI.
In hoofdstuk 3 onderzochten we de invloed van genetisch en omgevingsfactoren 
als voorspellers voor FXPOI door deze factoren met de leeftijd van menopauze te 
associëren. Door middel van een grote epidemiologische studie onder fragiele X 
families en een algemeen bevolkingscohort werden van verschillende risico­
factoren het effect op de leeftijd van menopauze bij FMR1 premutatie draagsters 
onderzocht. De grootte van de CGG herhaling was bij premutatie draagsters het 
meest geassocieerd (hazard ratio 1.43) met menopauze leeftijd. Daarnaast had 
roken een significant effect (hazard ratio 1.34) op leeftijd van menopauze bij zowel 
premutatie draagsters als niet-draagsters. We hebben een voorlopig predictie 
model ontwikkeld, gebaseerd op de grootte van de CGG herhaling, roken en de 
menopauze leeftijd van eerstegraads familieleden (met dezelfde mutatiestatus).
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Met dit model kan de kans om op een bepaalde leeftijd postmenopauzaal te 
worden voorspeld worden met een marge van 7-10%.
In hoofdstuk 4 werd de potentie van een ovariële reserve marker, anti-Mulleri- 
aans hormoon (AMH), als factor voor het ontwikkelen van risicoschattingen voor 
FXPOI, onderzocht. Het effect van de leeftijd waarop het hormoon bepaald werd 
en het hebben van de premutatie werden in het model verwerkt om een 
voorspellende AMH waarde (‘modeled AMH value’) te ontwikkelen. De mate 
waarin deze gemodelleerde AMH waarde afwijkt van de gestandaardiseerde 
AMH waarde was relatief stabiel in de tijd, zoals aangetoond door een intra- 
individuele correlatiecoefficient van 0.36 voor niet-draagsters en 0.69 voor 
premutatie draagsters. We concluderen hieruit dat gestandaardiseerd AMH als 
een voorspeller voor FXPOI gebruikt kan worden.
In hoofdstuk 5 werd met behulp van genoom brede koppelingsanalyse gezocht 
naar een potentieel FXPOI modificerend gen. Het geïdentificeerde locus op 
chromosoom 15q25 had een LOD score van 2.39. Dit locus ter grootte van 7.54 
Mb (79.61 Mb - 87.15 Mb) bevat, gebaseerd op kennis over hun functie uit 
diermodellen en humane studies, verschillende kandidaat genen. Een eerste 
sequentie analyse van 2 kandidaat genen, PDE8A (geassocieerd met folliculo- 
genese) en CYP19A1 (rol in steroïdogenese), heeft tot op heden geen evidente 
causale mutaties opgeleverd. Een ander kandidaat gen in dit locus, CPEB1, werd 
recent geassocieerd met POI en wordt op dit moment onderzocht op de 
aanwezigheid van een causale genetische variant.
In hoofdstuk 6 beschrijven we een koppelingsanalyse in een Nederlandse familie 
waarbij in 2 generaties POI voorkomt. Op basis van het overervingspartoon lijkt in 
deze familie een monogene oorzaak het meest waarschijnlijk. Via onze koppelings­
analyse werd een locus op chromosoom 3q25 geïdentificeerd met een LOD score 
van 2.7. Dit locus bevat enkele genen die onder andere in ovaria tot expressie 
komen. Sequentie analyse van een kandidaat gen, IQSec1, bracht vooralsnog 
geen nieuwe genetische mutaties aan het licht.
In hoofdstuk 7 worden alle in dit proefschrift benoemde potentiële FXPOI 
voorspellers bediscusieerd met betrekking tot hun relevantie voor het ontwikkelde 
predictie model. Om dit voorlopige model te optimaliseren stellen wij voor AMH 
hierin te includeren. Alhoewel onze koppelingsanalyse tot nu toe geen duidelijk 
modificerend gen voor FXPOI heeft opgeleverd, kan verder onderzoek naar het 
door ons geïdentificeerde kandidaat locus op chromosoom 15 leiden tot een of 
meer genen die het ontwikkelen van FXPOI kunnen beïnvloeden. Deze kunnen 
als waardevolle parameters aan een predictie model worden toegevoegd. Hoewel 
het exacte mechanisme dat leidt tot FXPOI nog niet ontrafeld is, wordt geïmpliceerd 
dat verhoogde FMR1 mRNA waarden hierbij een rol spelen. Deze hypothese dient 
echter verder onderzocht te worden. Daarnaast kunnen nieuwe POI kandidaat
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genen waardevolle informatie over de etiologie van POI, en daarmee ook FXPOI, 
verschaffen. In hoofdstuk 7 wordt het belang van het vroeg identificeren van 
premutatie draagsters met een grote kans op het ontwikkelen van FXPOI benadrukt. 
Samenvattend laten we in dit proefschrift zien dat het zeker mogelijk is om met 
behulp van een predictie model een schatting te maken van de kans waarop een 
premutatie draagster FXPOI ontwikkelt, maar dat daarbij de complexiteit van 
deze aandoening optimalisatie van het voorgestelde model vereist voordat het in 
de klinische praktijk bij erfelijkheidsadvisering toegepast kan worden.
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te zitten. Dank voor je tomeloze inzet en je persoonlijke manier van begeleiden.
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zorgvuldig doornemen van de manuscripten.
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met alle deadlines steeds weer voor elkaar kreeg.
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resultaat.
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for finding the time to finish this with all its deadlines.
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gezellig koffie pauzes, traktaties en de gevulde snoeppot voor de afleiding.
148
#
#Dankwoord
Beste studenten, Marieke en Loes, dank voor het werk met includeren van 
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op tijd kunnen verzamelen.
Joyce en Mariëlle, mijn paranimfen en beste vriendinnen. Waar kan ik anders 
staan dan met jullie 2 naast me. Vanaf het eerste studiejaar onafscheidelijk en 
hebben we alles samen meegemaakt. De trouwe meiden-avond is door drukte in 
frequentie afgenomen, maar nog altijd even vertrouwd, intens en gezellig. Bedankt 
voor al jullie steun met opbeurende en ook relativerende woorden.
Dan zijn er nog een aantal andere vrienden die ik graag persoonlijk wil noemen 
en bedanken voor hun steun, interesse en begrip voor mijn afwezigheid, omdat er 
weer eens een deadline was in het voor de meesten toch al zo ingewikkelde 
proces van specialiseren en promoveren: Frederike, Godelief, Joyce V, Judith, 
Karin, Marc, Marcel, Mark, Martine, Milou, Natasja, Ralph, Roy H, René en Sebas.
Dames 8, de goede inspanningen in de buitenlucht en de derde helften waren 
een heerlijke uitlaatklep de afgelopen jaren.
Eef, lieve Sis, bedankt voor alle plezier en gezelligheid die we al jaren samen 
hebben en het steeds geïnteresseerd blijven vragen hoe het met mijn onderzoek 
ging.
Lieve paps en mams, jullie hebben me de mogelijkheid gegeven om mijn dromen 
waar te maken en me bijgestaan in alle fasen met advies en een luisterend oor. 
Bedankt dat jullie er altijd voor ons zijn. Ik ben er trots op dat jullie mijn ouders 
zijn. Ook al wonen jullie ver weg, één telefoontje en ‘the Nanny’ kwam voor Daan 
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lekkere maaltijden en hulp bij het opvangen van Daan.
lie interesse, de
Roy, lieverd, voor het omschrijven van jouw aandeel in het afronden van dit 
proefschrift is nooit voldoende ruimte. Zonder jou was het nooit gelukt. Je gaf me 
de tijd, ruimte en de rust die nodig was en wist de motivatie hoog te houden, 
terwijl je veel liever samen iets leuks was gaan doen. Na jaren van werken in jouw 
zomervakantie, ben ik deze zomer maar liefst 4 maanden thuis!
Wat is het leven toch mooi met jou naast me.
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Lieve Daan, ‘mama werken’ kon je al heel vroeg zeggen. Onze quality-time moest 
het vergelden, maar nu komt er een tijd dat ik ook thuis ben en de mama-dag van 
ons beiden is.
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Chapter 5, figure 3
Figure 3 Haplotypes based on SNP and microsatellite genotypes delineated 
a critical region ranging from SNP A-2092428 (79.61 Mb) to SNP 
A-2106264 (87.15 Mb)
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The unaffected individual II:13 also carries the disease haplotype, except for a small sub-region of 2.11 
Mb (SNP A-2181330 and D15S154). Genotypes from I:1 and I:2 were inferred. Physical position (Mb) of 
each marker is shown according to NCBI build 37.1.
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Figure 3 Haplotypes with microsatellite genotypes corresponding to chromosome region 3p25.1-3p24.3
0>
Symbol definitions
□ o Clear symbol m © Unknown0 ® Unaffected □ (5 Early menopause (before 45 y)
■ • Affected n © Abnormal hormone levels for age
Note that the patients share a common haplotype (black bar) extending from D3S3701 to D3S3613. Genotypes from 11:12, II :25, 11:26, 11:17, II; 18, 11:19, II :24, 11:13 are 
Inferred. Physical position (Mb) of each marker Is shown according to NCBI build 37.2.
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